Renal function in cardiac surgery - Clinical and experimental studies by Kolsrud, Oscar
Oscar Kolsrud 
1 
 
Renal Function in Cardiac Surgery 
Clinical and Experimental Studies 
 
 
 
Oscar Kolsrud 
 
 
 
Department of Molecular and Clinical Medicine 
Institute of Medicine 
Sahlgrenska Academy, University of Gothenburg 
Gothenburg, Sweden 
 
 
 
 
 
 
Gothenburg 2018 
 
Renal function in cardiac surgery – clinical and experimental studies 
2 
Cover illustration:  
The Heart, the Kidney and the Machine.  
Pencil on paper. Oscar Kolsrud 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
Renal Function in Cardiac Surgery 
© Oscar Kolsrud 2018 
oscar.kolsrud@vgregion.se 
 
ISBN 978-91-629-0495-1 (PRINT)  
ISBN 978-91-629-0496-8 (PDF) 
 
Printed in Gothenburg, Sweden 2018 
Printed by BrandFactory 
  
Oscar Kolsrud 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effort counts twice  
-A. Duckworth 
  
Renal function in cardiac surgery – clinical and experimental studies 
4 
 
 
Renal function in cardiac surgery 
Clinical and experimental studies 
Oscar Kolsrud 
Department of Molecular and Clinical Medicine, Institute of Medicine 
Sahlgrenska Academy, University of Gothenburg, Sweden 
ABSTRACT 
Background: Impaired renal function (measured as glomerular filtration rate (GFR)) is a well-
known problem after heart surgery and heart transplantation (HTx), affecting both short-term 
and long-term survival. The reason for this is multifactorial, but the use of heart-lung machine 
and cardiopulmonary bypass (CPB) is thought to be one of the causes. Whatever the cause, 
impaired kidney function after heart surgery is an important clinical problem. 
Aims: We wanted to investigate whether estimated GFR could replace measured GFR in the 
follow-up of HTx recipients and to assess the renal and survival outcome in our entire cohort 
of HTx patients. Also, we wanted to investigate the potential renoprotective effects of ANP in 
an experimental model of CPB, and to compare the renal effects of a colloid-based CPB-prime 
versus a crystalloid-based prime in adult patients undergoing heart surgery.  
Methods: Retrospective registry studies were performed to evaluate the agreement of three 
major estimation formulas for GFR to the measured values in about 400 HTx recipients. An 
animal study on 20 pigs was designed to compare the renal effects of ANP during CPB. A 
randomized controlled trial with 80 adult patients undergoing cardiac surgery was performed 
to compare the renal effects of a dextran 40-based fluid to a conventional crystalloid-based 
fluid (Ringer-Acetate and mannitol) when used as priming solutions in the CPB circuit. 
Results: The agreement between estimated and measured GFR was very low, with a 
percentage error around 100%. Moreover, pre-HTx GFR did not predict mortality in our 
cohort. In our pig model, ANP increased GFR during CPB (p<0.0001) without increasing renal 
oxygen consumption. The patients receiving dextran 40-based priming solution in the heart-
lung machine had lower levels of the tubular injury marker NAG in their urine than the 
patients receiving crystalloid prime (p=0.045). 
Conclusions: Measured, not estimated, GFR should be used when assessing kidney function 
in HTx-patients. A GFR <30 ml/min/1.73m2 should not automatically exclude heart failure 
patients from HTx-evaluation. ANP is a drug with potential renoprotective properties that 
should be investigated further. A dextran 40-based priming solution seems to induce less renal 
tubular damage than crystalloid-based prime, and should be investigated further, specifically in 
patients with a preoperatively impaired kidney function. 
Keywords: Cardiopulmonary bypass, kidney function, acute kidney injury 
ISBN 978-91-629-0495-1 (Printed edition)  
ISBN 978-91-629-0496-8 (Electronic edition)   
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SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Njursvikt efter hjärtkirurgi med hjärt-lungmaskin är ett vanligt 
och allvarligt problem, som kan påverka överlevnaden efter en hjärtoperation. 
Orsakerna till den negativa effekten på njurfunktionen är många, men en av 
dem anses vara hjärt-lungmaskinen i sig. Hos hjärttransplanterade patienter 
anses även den livslånga behandlingen med mediciner som behövs mot 
avstötningen ha skadliga effekter på njuren på lång sikt. 
Mål: Vi ville studera njurfunktionen hos hjärtopererade patienter ur flera 
synvinklar: Kan enklare metoder för att beräkna njurfunktion ersätta den 
dyrare metoden att mäta njurfunktion hos patienter som hjärttransplanterats? 
Och hur påverkar patienternas njurfunktion innan hjärt-transplantation 
överlevnaden och njurfunktionen efter transplantationen? Förmakspeptid 
(ANP) är ett läkemedel som används för att förbättra njurfunktionen vid 
njursvikt efter hjärtkirurgi. Kan ANP givet redan innan och under 
operationen förhindra att njursvikt uppkommer? Kan man reducera 
njurskadan om man i hjärt-lungmaskinen använder en priming-vätska med 
högre kolloidosmotiskt tryck, och som därmed liknar kroppens egna vätskor 
mera? 
Metoder: Vi använde retrospektiva registerstudier för att jämföra beräknad 
och uppmätt njurfunktion hos hjärttransplanterade patienter, samt för att 
undersöka njurfunktionens betydelse för överlevnaden. För at undersöka 
ANPs effekter på njuren under hjärtoperation med hjärt-lungmaskin, 
utvecklade vi en stordjursmodell på gris. I en randomiserad studie på 
patienter som behövde hjärtoperation jämförde vi hur två olika vätskor i 
hjärt-lungmaskinen påverkade njurfunktionen. 
Resultat: Den beräknade njurfunktionen stämde mycket dåligt överens med 
den uppmätta njurfunktionen. Vi fann även att njurfunktionen innan 
hjärttransplantationen inte påverkade överlevnaden efteråt. I vår studie på 
grisar fann vi tecken på att ANP har en njur-skyddande effekt, och en vätska 
med högre kolloidosmotiskt tryck i hjärt-lungmaskinen orsakade mindre 
njurskada än den vanliga vätskan. 
Konklusioner: När man fattar beslut om patienter som skall bli, eller har 
blivit, hjärttransplanterade, bör njurfunktionen mätas, inte beräknas. 
Dessutom bör en dålig njurfunktion inte utesluta en patient med svår 
hjärtsvikt från transplantationsutredning. ANPs möjliga njur-skyddande 
effekt bör utredas närmare, och priming-vätskor med högre kolloidosmotiskt 
bör även provas på patienter med sämre njurfunktion. 
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INTRODUCTION 
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Heart surgery 
Background 
Since its wavering beginnings in the late 40’ies, cardiac surgery has gone 
through a tremendous development, both technologically and 
demographically. The high gains and eventually good outcomes have turned 
it into a surprisingly safe routine procedure performed on hundreds of 
thousands of patients of all ages annually. The range of heart diseases now 
accessible to surgical correction spans over a wide variety of both congenital 
and acquired diseases, among them ischemic heart disease, the single most 
common cause of death worldwide1. When performed on the correct selection 
of patients, heart surgery prolongs life, reduces morbidity and relieves 
symptoms2-4. Figure 1 on opposite page depicts a typical operating room 
while preparing for heart surgery. 
Regular heart surgery 
The high prevalence of heart diseases in the population, in particular the 
acquired diseases like ischemic heart disease or aortic valve stenosis, 
continues to be the foundation for the majority of the surgical heart 
procedures, e.g. coronary artery bypass grafting or aortic valve replacement. 
Also, the correction of other heart valve diseases like stenosis or regurgitation 
of the mitral valve or of aneurysms of the ascending aorta, all potentially 
deadly afflictions, adds to the number of diagnoses that can be successfully 
remediated.  
The correction of congenital heart disease, often in very young patients like 
new-borns or toddlers, is numerically performed in smaller volumes than 
surgery on the acquired diseases are, but the gain in life-years is, not 
surprisingly, much more pronounced when correcting congenital defects than 
in surgery aimed at the acquired diseases in a much older population5,6. 
Heart transplantation 
The possibility to remove a terminally failing heart and replace it with a new, 
healthier one, stands in a special position within surgical treatment for heart 
diseases. The first human-to-human heart transplantation was performed by 
Christiaan Barnard in Cape Town, South Africa, 1967. It is important to 
remember that initially, this ultimate surgical procedure did not perform 
particularly well, and with discouraging results with few patients surviving 
more than a year after transplantation, the procedure quickly fell out of 
favour. However, with the advent of modern immunosuppressant therapy, in 
particular the calcineurin inhibitors (CNI), heart transplantation was 
Oscar Kolsrud 
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transformed into an established treatment for terminal heart failure during the 
1980’ies7.  
Though this treatment is performed in much smaller volumes than other heart 
surgery, the immunosuppressive regimen of today have improved long-term 
survival dramatically, adding 10 life-years or more to 60 % of patients who 
were otherwise expected to live only for a few years, or even months, with 
the agonizing symptoms of a terminally failing heart, and has thus become a 
treatment of tremendous importance for the individual patient8. 
 
Figure 1: Picture from the author’s workplace showing a typical operating room 
while preparing for heart surgery. The heart-lung machine is in the front, with 
reservoir and oxygenator (in white) on lower left side. (Photo by Carl Johan Malm, 
2012). 
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The heart-lung machine  
History 
Modern day heart surgery would be unconceivable without the invention of 
the heart-lung machine. John Gibbon is credited with developing the first 
heart-lung machine, and performed the first successful operation using such a 
machine in 1953 in Philadelphia, USA, when he corrected a congenital heart 
defect, an atrial septal defect, on an 18-year-old girl9. This technological 
breakthrough provided the surgeons with the possibility to operate on an 
empty, flaccid heart for a prolonged period of time, while the rest of the 
patient’s body was perfused with oxygenated blood. This opened up the field 
of heart surgery to much more complex and delicate procedures than had 
previously been possible. Needless to say, heart transplantation would be 
impossible without such an invention. 
 
 
 
Figure 2: General principle of the heart-lung machine. Desaturated (oxygen-
poor) blood is drained from the right atrium of the heart, collected in a 
reservoir, passed through an oxygenator and finally pumped back into the 
aorta.  (Ill: Blausen medical communications, Inc., CC Creative Commons.) 
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Technique 
During the typical cardiac surgery procedure, after opening the chest, the 
surgeon connects the heart-lung machine by cannulas to the ascending aorta 
and the right atrium of the heart (though other variants for cannulation are 
also possible). The desaturated (oxygen depleted), venous blood is drawn 
from the right atrium, drained into the reservoir of the machine, passed 
through an oxygenator and finally pumped back into the ascending aorta, 
completing a standard cardiopulmonary bypass (CPB) circuit (Figure 2). The 
dimensions of the cannulas and tubes in the system, as well as the pump 
speed, are chosen and adjusted to provide a “full CPB blood flow”, i.e. totally 
alleviating the heart from the requirement of performing any pumping action 
to keep the tissues of the body oxygenated. Thereafter, the surgeon can 
exclude the heart from the systemic circulation by clamping the ascending 
aorta, induce asystole by injecting cardioplegia (usually a solution with a 
high concentration of potassium), and perform the planned surgery on a 
bloodless, motionless heart. Whether the heart-lung machine should mimic 
the heart and deliver a pulsative flow, or whether it suffices to have a steady, 
non-pulsative flow, is not known. The effects of pulsative versus non-
pulsative flow on the organs are still, more than sixty years after the 
invention of the machine, being debated10. (At the Sahlgrenska University 
Hospital, non-pulsative flow is routinely being used during CPB.) At 
completion of the corrective procedure, the surgeon removes the aortic clamp 
to allow the blood to flow into the coronary circulation again, and through the 
ensuing washout of cardioplegia from the myocardium the beating action of 
the heart will automatically return. When the heart has regained it’s rhythm 
and strength, the patient is weaned from the heart-lung machine, and the 
surgeon can remove the cannulas from the right atrium and the ascending 
aorta and close the chest. 
The priming 
Before commencing CPB, the reservoir and tubes of the heart-lung machine 
obviously have to be pre-filled, primed, with fluid of some sort to avoid the 
pumping of air into the circulation. To prime the system about 1200 ml of 
fluid is usually required. At initiation of CPB, this fluid will be pumped into 
the patients’ circulation, and will mix with the patients’ blood. Consequently, 
it seems reasonable that the composition of this priming fluid should to some 
degree mirror that of the blood and bodily fluids. Most priming fluids 
therefore consist of a solution with a physiological concentration of 
electrolytes (i.e. a crystalloid solution), such as the Ringer solution, often 
with additives such as heparin or mannitol. Since the composition of human 
plasma is much more complex, and also contains a whole range of colloids 
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(larger molecules unable to pass freely over the cell- or basal membranes), 
the addition of colloids to the priming solution is also used in many 
centres11,12.  
Such colloids generate oncotic (or colloid osmotic) pressure in the fluids in 
the body. The higher the concentration is of these molecules, the higher the 
oncotic pressure. Somewhat semantically confusing, the oncotic pressure is 
actually a negative pressure, sucking water and electrolytes across a 
semipermeable barrier from solutions with a lower oncotic pressure to 
solutions with a higher oncotic pressure. In the body, the semipermeable 
barriers separating these solutions are the cell- and basal membranes of the 
capillaries, such as the glomeruli in the kidneys (see kidney physiology 
section). In order to exert oncotic pressure, the molecules have to be bigger 
than the gaps in these semipermeable borders. Of particular interest in this 
thesis is the role of oncotic pressure in the renal circulation (see Paper IV). 
The glomerular membrane allow molecules smaller than 6 kDa (kiloDalton) 
to pass unhindered, but is virtually impenetrable to molecules larger than 60 
kDa13. The most important natural colloid is albumin, a 69-kDa protein 
synthesized in the liver that constitutes almost 80% of the oncotic pressure of 
plasma14. 
However, systematic and definitive comparisons of crystalloid-based versus 
colloid-based priming solutions are scarce, and further studies that could help 
determine the composition of the optimal priming solution are warranted15.   
Concerns 
However marvellous the invention of the heart-lung machine, the exposure of 
the blood to this kind of extracorporeal circulation, also has numerous 
negative side effects. Not being lined with vascular endothelium, the inner 
surfaces of the tubes and reservoirs of the machine are perceived as a giant 
foreign body by the several litres of blood that passes through the system 
each minute. This blood–to-foreign-body contact unleashes a host of 
inflammatory responses16: the intrinsic coagulation pathway; the fibrinolytic 
system; and the complement system are all activated. Cytokines like TNF, 
IL-1, IL-6 and IL-8 are released, and there is cellular activation of platelets, 
endothelial cells and leukocytes. The ensuing systemic inflammatory 
response is believed to be the cause of the multiple adverse effects observed 
in several different organ systems after CPB. These are described in brevity 
below: 
Oscar Kolsrud 
19 
Vasodilatory shock/vasoplegia 
A profound loss of vascular tone and accompanying hypotension 
(MAP<50mmHg) poorly responsive to conventional vasopressor treatment is 
called vasoplegia, and seen in 5%-25% of patients immediately after CPB. 
The condition is thought to be caused by cytokine-induced activation of iNO-
synthase and ATP-dependent potassium channels, resulting in hyper-
polarization of endovascular membrane and release of the vasodilator 
substance nitric oxide (NO)17. The mortality has been reported to be as high 
as 10%18. 
Coagulopathy 
Needless to say, bleeding is a common and important problem in heart 
surgery. Adding harm to injury, the use of CPB affects and impairs 
haemostasis on several levels. The CPB priming volume causes 
haemodilution and reduction of platelet count, and the CPB itself induces 
thrombocyte dysfunction and increased fibrinolysis19. Around 5 % of patients 
undergoing heart surgery in Sweden need reexploration for bleeding20, and 
excessive bleeding is, not surprisingly, associated with increased risk for 
mortality21,22. 
Neurocognitive dysfunction 
Postoperative delirium is a condition that engages medical staff of all 
categories that are involved in the postoperative care of heart surgery 
patients. The patients that are affected can experience delusions, 
hallucinations or paranoia that luckily usually subsides spontaneously within 
days. Different studies have shown that it affects between 3-31%23 of heart 
surgery patients and believed to be at least partially caused by the systemic 
inflammation disrupting the blood brain barrier, leading to a 
neuroinflammatory process24. 
A subtler but more long-standing cognitive impairment than delirium is the 
effects on memory, attention and language comprehension, on both short-
term and long term25. 40% of patients have been reported to have measurable 
cognitive decline 5 years after surgery. The aetiology of this negative 
cognitive effect is believed to be cerebral microembolisation of lipid-, gas- or 
other particulate origin26. 
Pulmonary dysfunction 
After CPB, impaired lung function is seen in as many as 12%, with another 
1.3% developing the more severe adult respiratory distress syndrome 
(ARDS)27. About 5% of patients in Sweden need mechanical ventilation for 
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more than 48 hours after heart surgery20. Again, an inflammatory response 
seems to be the cause. Activated neutrophils and matrix metalloproteinases, 
increased myeloperoxidase, IL-8 and elastase levels all contribute to 
destruction of lung tissue28-30. The majority of these patients recover, but 
severe lung injury has been shown to have a mortality of over 50%31. 
Kidney dysfunction 
Impaired renal function after heart surgery and CPB, acute or chronic, is seen 
in up to almost a third of patients, and is associated with prolonged 
hospitalization, ICU stay and even increased mortality32-36.  
The effect of heart surgery on renal function lies at the heart of this thesis, 
and kidney dysfunction and physiology are therefore described in more detail 
in the following sections. 
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Kidney dysfunction after cardiac surgery 
Background 
The development of acute kidney injury (AKI) is a well-known complication 
after heart surgery and cardiopulmonary bypass (CPB). Up to 30% of patients 
is affected and the condition is associated with a fivefold increase in 
mortality32-35. If a patient develop an AKI so severe that renal replacement 
therapy (RRT/dialysis) is needed, the condition is associated with a 30-day 
mortality of up to 50 %36. In Sweden, 2.5% of patients undergoing cardiac 
surgery in 2016 developed this most severe form of AKI20.  
Even if heart transplant recipients do not develop AKI in the immediate 
conjunction with the transplantation, they are still at risk for developing 
chronic kidney disease later on, often after several years. The prevalence of 
this condition increases over time37 and consequently becomes an 
increasingly important cause of death as time goes by. After 10 years, almost 
10% of deaths are attributed to renal failure8. 
The special importance of GFR in heart transplantation 
Renal function plays a particular role in solid-organ transplantation of any 
kind, not only in patients undergoing kidney transplantation37.  The problem 
of renal dysfunction after solid-organ transplantation (i.e. not including blood 
transfusion or bone marrow transplantation) was well known already at the 
beginning of the HTx era, based on experiences from liver-, lung- and kidney 
transplantation. With this in mind, renal dysfunction was already from the 
beginning considered a relative contraindication for HTx. The ISHLT 
guidelines for HTx still have a lower limit for renal function, below which 
the renal function is considered a relative contraindication for HTx. This 
means that when a patient is evaluated for HTx, a low GFR will usually be 
weighed in as a negative factor, implying that the patient could be denied 
listing for HTx. This is an understandable strategy, since the early HTx-
attempts in the 60-ies and 70-ies had demonstrated discouraging results in 
long-term survival, and excluding patients with renal dysfunction was 
conceived as one way to improve the results. However, controversy still 
remains about the exact level at which a reduced GFR (Glomerular Filtration 
Rate, see 1.4.2) should be considered a risk factor for transplantation. At the 
24th Bethesda conference in 1993, a creatinine clearance less than 50 ml/min 
was considered secondary exclusion criteria for HTx38. In 2006, the 
International Society of Heart and Lung Transplantation (ISHLT) 
recommended that a pre-transplant GFR of 40 ml/min/1.73m2 or less should 
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be considered as a relative contraindication to HTx39. In the ISHLT 2016 
guidelines40 this level was further reduced to 30 ml/min/1.73m2. 
Complicating the consideration of pre-HTx renal function is the possibility of 
a pre-renal cause of the condition, i.e. the heart failure itself. The kidneys 
might be suffering from the low cardiac output, but may be otherwise 
unaffected, and will regain their normal function once the failing heart is 
exchanged for a new, healthier one. 
More research regarding the importance of pre-HTx renal function and its 
effect on outcome after transplantation is needed to facilitate decisions 
regarding which patients should be listed for HTx, and how to handle their 
renal function post-transplantation, both short-term, immediately after HTx 
and long-term, in the years afterward. The importance of pre-HTx kidney 
function is a particular subject of interest in Paper I and Paper II. 
 
Acute Kidney Injury 
Definition 
The general definition of acute kidney injury (AKI) is a syndrome featured 
by a relatively rapid loss of renal excretory function diagnosed by decreased 
urine output or accumulation of nitrogen metabolites, or both. However, the 
more specific definition of this condition has undergone several revisions 
over the years, and the lack of a uniform definition has made the 
epidemiology of AKI difficult to assess with precision. The earlier RIFLE 
criteria41 (Risk, Injury, Failure, with Loss of kidney function and End-stage 
kidney disease as outcome criteria) and AKIN-criteria42 (the Acute Kidney 
Injury Network) have now been combined into the KDIGO criteria (Kidney 
Disease: Improving Global Outcomes).  What they all have in common is a 
defined increase in serum creatinine from baseline within a defined 
timespan43. The KDIGO criteria now defines AKI according to the following 
criteria44: 
• Increase in serum creatinine by ≥26.5 µmol/l within 48 
hours; or 
• Increase in serum creatinine by ≥1.5 times baseline which is 
known or presumed to have occurred within the prior 7 
days; or  
• Urine volume <0.5ml/kg/hour for 6 hours  
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Pathophysiology 
The development of surgery-associated AKI is considered to be a 
multifactorial process. In cardiac surgery the patient is not only exposed to a 
major surgical trauma, but also to the use of cardiopulmonary bypass. The 
use of heart-lung machine/CPB has been shown to trigger the systemic 
inflammatory response syndrome (SIRS) and to contribute to haemolysis and 
micro-embolization45, all with negative renal effects. In addition, 
haemodilution, hypotension, renal vasoconstriction and impaired auto-
regulation of renal blood flow during CPB also have the potential to impair 
oxygen delivery to the kidneys46-48. The renal medulla, utilizing large 
amounts of oxygen for tubular sodium reabsorption (renal physiology 
section), is on the verge of hypoxia already under normal conditions and 
therefore particularly susceptible to acute renal ischemia49. 
Ischemic damage to the endothelial cells in the renal microvasculature leads 
to cellular and interstitial oedema, and to cell debris being shed into the 
lumen50. This causes further impairment of renal perfusion, and the resulting 
medullar ischemia can cause the tubular epithelial cells to die, a condition 
known as acute tubular necrosis (ATN). The normal functions of the tubules 
are consequently disrupted as they are no longer are able to perform their 
reabsorptive or excretory functions. Necrotic tubular cells are shed into the 
tubular lumen, causing obstruction of the nephrons51. 
In the pursuit to find a clinical biomarker to detect ATN, N-acetyl-β-
glucosaminidase (NAG) has been identified, amongst others. NAG is a 
lysosomal enzyme produced in tubular cells, mostly in the proximal tubules 
in the renal medulla. Urinary secretion of NAG has been shown to be 
associated with tubular necrosis in cardiac surgery patients, and analysis of 
urinary NAG can thus be used for detecting tubular damage52-55. 
 
Chronic kidney disease 
According to KDIGO, chronic kidney disease (CKD) is defined as a GFR 
less than 60 ml/min/1.73m2 (if no other markers of kidney disease)56, and 
kidney failure is defined as GFR <15. However, over the years these 
definitions have varied. 
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As mentioned above, chronic renal failure is a problem in all solid-organ 
transplantations37. After heart transplantation, renal failure (in this case 
defined as GFR <30 ml/min/1.73m2) has been reported in as many as 41% of 
patients after 10 years57, and renal failure becomes an increasingly important 
cause of death as the years pass by8. In comparison, the prevalence of such a 
low GFR (<30) is less than 1% in the total population58,59. 
The aetiology of chronic kidney disease after heart transplantation is 
multifactorial60. A biopsy study identified both sequelae from the 
perioperative acute kidney injury as well as long-term effects of hypertension 
and diabetes (which are also the most common causes in the population at 
large), as well as treatment with nephrotoxic immunosuppressant drugs like 
calcineurin inhibitors (CNI). CNI is believed to have both acute and chronic 
nephrotoxic effects61, though the exact mechanisms and their relations to the 
other non-CNI factors like hypertension and diabetes is still debated60. 
Nevertheless, due to the well documented risk of developing CKD after 
transplantation, the pre-transplantation GFR level has, since the beginning of 
the HTx era, been considered an important factor to consider when deciding 
whom to accept, or not to accept, for HTx listing.  
The importance of pre-HTx GFR for long-time survival after HTx is one of 
the questions investigated in Paper II. 
 
Treatment 
Acute kidney injury 
In addition to the injury the kidney sustains from the CPB and the associated 
traumas mentioned above, the kidney might also suffer under a low cardiac 
output from a failing heart. Therefore, in treating AKI after heart surgery, a 
“pre-renal” cause of the impaired kidney function must also be suspected, 
and detected early. The heart function should therefore be monitored closely, 
and signs of heart failure should be treated with inotropic agents such as 
isoprenaline, dopamine, milrinone or norepinephrine. Postoperative 
pulmonary hypertension leading to a right ventricular failure could be treated 
with inhaled prostacyclin or nitric oxide. 
The clinical results of pharmacological treatment of acute renal failure 
targeting the kidney directly have been contradictory at best, but mostly 
disappointingly unsuccessful, though several regimens has been tried, and 
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tested. The idea is that diuretics could protect the kidneys from AKI through 
a decrease in renal oxygen demand, and increased diuresis; the latter 
protecting the tubules from tubular occlusion. However such effects have 
been difficult to demonstrate62. 
- Loop diuretics derive their name from their effect on the part of the nephron 
called the Loop of Henle where it inhibits the reabsorption of sodium, 
chloride and potassium. Although they have several other effects on the 
nephron, the main diuretic effect stem from the inhibition of sodium 
reabsorption, and the concomitant decreased reabsorption of water from the 
tubuli. However, even if loop diuretics increases the volumes of urine, no 
reduction in morbidity, mortality or need for dialysis has been found63. 
- Mannitol is a small 0.182 kDa monosaccharide that is not metabolized and 
is eliminated from the circulation only by glomerular filtration. Thus, due to 
its small size, it freely passes over the glomerular membrane into Bowman’s 
capsule. It works as an osmotic diuretic, and has been shown to increase GFR 
in postoperative cardiac surgery patients64 and probably also deswelling of 
endothelial cells and tubular cells injured by hypoxia65,66. However, like loop 
diuretics, no effect on AKI outcome has been demonstrated67. 
- Dopamine increases diuresis through renal vasodilatation, inhibiting the 
reabsorption of sodium in the proximal tubules of the nephron, and increasing 
GFR. However, it has not been shown to affect the renal outcome of AKI68,69. 
- Atrial natriuretic peptide (ANP) is a hormone peptide with diuretic effects. 
The possible renoprotective effect of ANP has been discussed, and a 
systematic review and meta-analysis in 2009 recommended further studies 
particularly in patients undergoing cardiac surgery70. ANP is described in 
more detail in 1.4.2 and 3.3. 
Given the inability of diuretics to show any improvements in clinical 
outcome, the 2012 KDIGO Guidelines state that diuretics should not be used 
to treat AKI, except as a way to treat fluid overload71. 
If the AKI progresses to renal failure, dialysis, in the form of continuous 
renal replacement therapy (CRRT) might be necessary as a last resort.  
Fortunately, the renal function in most patients that develop post-CPB AKI 
recovers, but as mentioned above, the condition still is associated with a 
fivefold increase in mortality, and around 2.5 % develops the need for CRRT, 
which carries a staggering 30-day mortality of up to 50 %36. 
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Avoiding the AKI and the ensuing renal failure with some prophylactic 
strategy would be a better option, both from the patient’s perspective, and 
from an economical perspective. But as pointed out above, no convincing 
such renoprotective therapy has been identified, but mannitol is often added 
to the CPB priming or during the CPB11,12. At the Department of 
Cardiothoracic Surgery at Sahlgrenska University hospital, ANP is often 
applied postoperatively in the treatment of patients with AKI. 
Chronic kidney disease 
The principal strategies for treating chronic kidney disease involves, apart 
from treating the cause, amending the metabolic consequences, adjusting the 
blood pressure and level of hydration, and correcting electrolyte levels. In 
particular, any nephrotoxic drug should be removed or the dosage reduced. In 
transplanted patients, the problem is of course that the most effective 
immunosuppressive therapy is based on CNI, which is well known for its 
nephrotoxic effects61. The reduction of CNI, while not compromising with 
the immunosuppressive effect, is a subject of much research. As with AKI, 
diuretics are not compulsory unless the patient suffers from over-hydration, 
or needs correction of potassium levels. As a last resort, dialysis, and maybe 
even kidney transplantation, must be considered. When chronic kidney 
failure finally develops into such a severe state that dialysis or kidney 
transplantation is needed, the patient is often said to have reached end stage 
renal disease (ESRD)41. 
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Kidney function 
Renal physiology 
The kidney is a complex organ that has several important functions; excretion 
of waste products, secretion of hormones, gluconeogenesis (producing 
glucose) and the homeostasis of pH and blood components. It is far beyond 
the scope of this thesis to describe renal physiology in any depth, and only 
what is most relevant in the context of this thesis will be mentioned briefly. 
The kidney performs its production of urine through filtration, reabsorption 
and secretion. The functional units of the kidney are the nephrons (see Figure 
3) that produce and carry the filtrated fluid from the blood to the calyx of the 
kidney. When blood enters the kidney it is first passed through the 
glomerulus, a small sphere of winding capillaries. The glomerulus is 
surrounded by Bowmans’s capsule into which massive amounts of fluid are 
filtrated from the blood. This primary urine, or ultrafiltrate, is then passed 
down the nephron where over 99% of the filtrate is reabsorbed in the tubules. 
 
Figure 3: Kidney anatomy: on the left, the cortex (light brown) and the medulla  
(pink), and on the right the functional unit of the kidney; the nephron.  
(Shutterstock, Standard license.) 
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The filtration of fluid from the glomerulus into Bowman’s capsule through 
several layers of semipermeable membranes (the capillary endothelial cells, 
the basement membrane and the epithelial cells of Bowman’s capsule, which 
allow only small molecules to pass13. Molecules with a molecular weight of 5 
kDa pass through this glomerular membrane unhindered. In this situation the 
permeability of the membrane is defined as 1.0. The permeability for 30 kDa 
molecules are only 0.5. Above 60 kDa, the permeability is very low. To 
albumin, the most common of the serum proteins, and also the smallest, with 
a molecular weight of 69 kDa, the permeability is only 0.005. To other 
important serum proteins, like immunoglobulins (150 kDa), essential for the 
immune defense, and fibrinogen (340 kDa), essential for blood clotting, the 
glomerular membrane is, for all practical purposes, impenetrable. In effect 
the primary urine produced in the corpuscle, the glomerular filtrate, is the 
same as plasma, except that it contains negligible amounts of proteins. 
The amount of fluid filtrated from the blood into Bowman’s capsule is 
determined by the differences in net filtration pressure over the 
semipermeable membranes. This pressure-gradient is generated both by the 
blood hydrostatic pressure itself, but also by the colloid osmotic (or oncotic) 
gradient between the glomerulus and Bowman’s capsule.  
Accordingly, the filtration pressure, and thus the amount of fluid filtrated, can 
be regulated by modulation of any of these pressures. 
The afferent and efferent arterioles: Each glomerulus is supplied by a single 
afferent arteriole, and on the opposite end the capillaries of the glomeruli 
converges back to one single efferent arteriole. Both the afferent and the 
efferent arteriole has the ability to constrict or dilate, which can be use to 
regulate the impediment to blood flow in these segments. When the afferent 
arteriole dilates, the glomerulus is exposed to a higher pressure, which can be 
further accentuated by a constriction of the efferent arteriole. By this 
mechanism, and regulated through both myogenic mechanisms and by 
tubuloglomerular feedback mechanisms, the blood flow and the hydrostatic 
pressure in the glomeruli can be regulated. 
The glomerular oncotic pressure: The glomerular oncotic pressure is 
generated by the colloid particles unable to cross the semipermeable barrier 
lining the capillary walls of the glomerulus. Thus, the nature and amount of 
colloid particles will influence the filtration pressure, and the GFR. 
About 20% of the cardiac output goes through the kidneys, which amounts to 
about 1200 ml/min in an adult person. The rate of production of ultrafiltrate 
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each minute in both kidneys, the glomerular filtration rate (GFR), is 
approximately 125 ml/min. This means that each day almost 2000 litres of 
blood is passed through the kidneys, and almost 180 litres of primary urine is 
produced. Since almost all of the fluid that enters the tubuli is reabsorbed, the 
final amount of urine is only 0.5-2 litres (0.5-1 ml/kg/hour) a day. 
As the massive amounts of ultrafiltrate are passed through the tubuli, the 
fluid and its constituents is processed in a number of important ways, both 
passive (i.e. not requiring energy) and active (i.e. requiring energy). The fact 
that the processing of certain substances requires energy is an important point 
in renal physiology. Energy expenditure also increases oxygen consumption, 
and thus the oxygen demand of the renal tissues. If this increased demand is 
not matched by an increased delivery, the ensuing oxygen supply/demand-
mismatch may result in renal hypoxia and tubular damage or necrosis. 
Substances are selectively absorbed or secreted during the tubular passage, 
and this allows the kidneys to separate substances that are to be conserved in 
the body, from substances that are to be eliminated in the urine. The most 
important substance to be actively reabsorbed in the tubuli is sodium ions 
(Na+). Also, glucose, amino acids, chloride ions, phosphate, calcium, 
magnesium and hydrogen ions are actively co-transported, coupled to the 
energy-consuming action of the pumping of sodium ions into the interstitium, 
and reabsorbed from the fluid together with sodium. The water-molecules 
themselves move passively out of the tubuli through osmosis as the 
concentration of osmotic active substances (like Na+) decreases in the tubuli 
and increases in the interstitium. 
Substances that are actively secreted include hydrogen ions, potassium ions 
and urate ions 
The kidneys play an important role in regulating the acid-base balance by 
secreting hydrogen ions into the tubular lumen of the nephrons, balancing the 
bicarbonate ions that are continuously filtered from the glomerulus into the 
proximal tubules. Any impairment of the tubular epithelial cells ability to 
excrete hydrogen ions into the tubular lumen will result in a build-up of 
hydrogen ions in the body, thereby threatening to lower the pH-level, which 
is normally tightly regulated within the range of 7.35-7.45. 
Atrial natriuretic peptide 
Several substances and hormones are involved in regulating renal function, 
such as endothelin, angiotensin II, aldosterone, antidiuretic hormone (ADH), 
parathyroid hormone (PTH), bradykinin and natriuretic hormones. However, 
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only natriuretic hormones have direct relevance for this thesis, and 
accordingly this text will focus mainly on them, in particular the atrial 
natriuretic peptide. 
The natriuretic peptide system is primarily an endocrine system that 
maintains fluid and pressure homeostasis by modulating cardiac and renal 
function. At least eight natriuretic peptides have been discovered so far, of 
which the most well known are the atrial natriuretic peptide (ANP), the brain 
natriuretic peptide (BNP) and the C-type natriuretic peptide (CNP)72. 
ANP was the first of the natriuretic peptides to be discovered, and is a 28-
amino acid peptide hormone produced in the cardiac muscle cells in the atrial 
wall (Figure 5). Already in the 1950’ies, electron microscopy suggested that a 
substance was generated in the cardiomyocytes of the atria of guinea pig’s 
hearts73, though the effects of the substance were not discovered until 
197974,75. ANP is released continuously from the heart and the rate of release 
increases in response to atrial stretch, will cause vasodilation, natriuresis, and 
inhibition of the sympathetic nervous system and the renin–angiotensin–
aldosterone axis76. In the distal convoluted tubuli and the cortical collecting 
duct, ANP decreases sodium reabsorption, thereby reducing the reabsorption 
of water, which induces natriuresis and diuresis. In healthy volunteers and in 
post-cardiovascular surgery patients with normal renal function, the majority 
of studies have shown that the natriuretic response to ANP is associated with 
an increase in GFR76-80. Such an increase in GFR will also increase the 
tubular sodium load, renal sodium reabsorption and consequently renal 
oxygen consumption (RVO2). On the other hand, experimental data suggest 
that ANP inhibits tubular sodium reabsorption in the collecting ducts of the 
medulla, which would decrease RVO2.81,82 
Thus, ANP seems to have several effects on kidney function, not all of them 
very well understood. 
Clinically, recombinant human ANP has been approved in Japan to treat 
patients with heart failure since 199583. At the Sahlgrenska University 
Hospital, ANP is used under licence for treating AKI after cardiac surgery 
and heart transplantation.  
The effects of ANP on renal function during cardiopulmonary bypass are the 
focus of the investigations presented in Paper III. 
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How do we assess kidney function? 
At the most fundamental level, the definition of “kidney function” depends 
on the perspective of the investigator, i.e. which of the renal “functions” is to 
be measured. However, a universally accepted definition of kidney function 
is to state the glomeruli’s capability to filter fluid out of the passing blood. In 
the practical setting, to measure the amount of ultrafiltrate from the glomeruli 
per time unit, (ml/minute, i.e. the glomerular filtration rate, GFR) one would 
need a particle with some ideal properties for the task: It should be filtered 
freely across the semipermeable membranes, and not be reabsorbed or 
excreted in the tubuli. Also, it should not be metabolized or eliminated in any 
other way than through the urine. The measurement of the concentrations of 
this substance in blood or urine could then be used to calculate the amount of 
fluid filtrated. Different exogenous and endogenous substances and 
techniques are being used to this end, like inulin, iohexole and 51Cr-EDTA, 
and even substances with less ideal properties, like creatinine and cystatin C. 
Creatinine in blood 
Creatinine is a final breakdown-product of muscle metabolism that is chiefly 
removed from the blood through the kidneys84. Being a small molecule 
(0.113 kDa) it is easily filtrated into Bowman’s capsule. However, very little 
reabsorption of creatinine occur (but some active excretion). If the kidney 
function is impaired in some way, the serum levels of creatinine will rise 
accordingly. This rise in levels of serum creatinine can thus be used to assess 
the kidney function. In women, the normal level of creatinine in serum is 45-
90 μmol/L, whereas in men it is 60-105. Above these levels, some degree of 
impaired renal function should be suspected. However, due to the several 
non-renal factors influencing the levels of creatinine, like age, sex, weight 
and muscular mass, the level of creatinine in serum or plasma is only a rough 
indicator of renal function85. Since creatinine is a breakdown product of 
muscle cells, the amount of muscle will affect the concentrations. Also, non-
renal metabolism of creatinine plays an increasingly important role with 
increasingly impaired kidney function. Furthermore, the creatinine levels can 
not be guaranteed to be raised above the normal range until 60% of the total 
renal function is lost84. 
Even though it is a relatively rough estimate of renal function, the plasma 
creatinine concentration holds the advantage of being a cheap routine blood 
sample analysis, and is therefore widely used in the daily clinical setting of 
decision-making in hospitals or outpatient receptions. 
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When a more precise description of the kidney function is needed though, 
some way of assessing GFR is necessary. 
Measured GFR (mGFR) 
Measuring the clearance of infused exogenous substances (with the ideal 
properties mentioned above) will give the most accurate assessment of GFR. 
Substances used for this purpose include inulin, iohexole and 51Cr-EDTA. 
This is called measured GFR, or simply mGFR. 
Inulin is a 5.2 kDa polysaccharide that easily passes through the glomerular 
membrane but is neither excreted nor reabsorbed in the tubuli, and has been 
considered the gold standard of GFR measurement. However, inulin is 
expensive and difficult to measure, and is rarely used clinically. Other 
substances with similar properties exist that are more practical in the clinical 
setting (though still more cumbersome and expensive than the measurement 
of creatinine). 
Iohexole is a 0.821 kDa contrast agent used for x-ray examination that also 
has ideal properties and can be analysed with high performance liquid 
chromatography-technique. EDTA is a metal ion binding chelating agent that, 
when loaded with the radioactive chromium isotope 51Cr forms 51Cr-EDTA, a 
0.342 kDa molecule, that is readily detected with radioisotopic methods. 
Both iohexole and 51Cr-EDTA have been shown to perform as well as inulin 
in measuring GFR86. 
Both iohexole and 51Cr-EDTA were used when measuring GFR in the studies 
included in this thesis. 
Estimated GFR (eGFR) 
Since measuring GFR with one of the methods mentioned above is both 
cumbersome and expensive, several methods for estimating GFR (eGFR) has 
been developed. The cheap and readily available routine blood sample 
analysis of creatinine levels (see above) is heavily influenced by non-renal 
factors, and does not describe GFR, but through mathematical equations that 
take these non-renal factors into account (like age, sex, weight, and in some 
cases even race) several formulas for estimating GFR from serum creatinine 
levels have been developed87-89. Similar formulas have also been developed 
for the Cystatin C, a 0.013 kDa protein that can be used as a biomarker for 
kidney function in a similar fashion as creatinine90, but since analysis of 
creatinine is far more common and ubiquitous in medical institutions, and is 
the biomarker of focus in this thesis, the role of Cystatin C will not be 
discussed further. 
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Three of the most well known creatinine-based formulas for estimating GFR 
are: 
• The Cockcroft-Gault formula. 
• The MDRD formula (Modification of Diet in Renal 
Disease). 
• The CKD-EPI formula (Chronic Kidney Disease-
Epidemiology collaboration). 
See Table 1 for the mathematical description of these formulas. Other 
formulas also exist, like the Swedish LM-rev formula (Lund-Malmö revised 
formula)91. The LM-rev formula seems to have promising estimating power92 
in a Swedish population, but has so far not been widely applied 
internationally and has not been included in the formulas studied in this 
thesis. 
For the day-to-day use in the clinical setting, these formulas often give 
sufficiently exact estimates of GFR. All of these formulas have their 
advantages and disadvantages, and their relevance is continually being 
evaluated in different groups of patients93,94. A 2013 report from the Swedish 
Council on Health Technology Assessment concluded that more studies are 
needed in several patient groups, e.g. patients undergoing organ 
transplantation or heart surgery93. 
In this thesis, the level of agreement between estimated GFR and measured 
GFR in heart-transplanted patients was studied to decide whether eGFR 
could replace mGFR at our department (see Paper I). 
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Table 0: Equations for estimating GFR (mL/min/1,73m2) based on age, sex, weight 
(kg) and creatinine (µmol/L).  
 
 
 
1. Cockcroft-Gault original formula87; (140 - age) x [(weight)/(72 x creatinine/88.4)]  (x 
0.85 if woman)  
2. Cockcroft-Gault (original formula) x 0.80 (IDMS traceable creatinine calibration (since 
2004-06-01))  
3. MDRD abbr formula; caucasian men88: 186 x (creatinine/88.4)-1.154 x (age) -0.203 (if 
woman: x 0.742)  
4. MDRD abbr formula; caucasian men: 175 x (creatinine/88.4)-1.154 x (age) -0.203 (if 
woman: x 0.742) (IDMS traceable creatinine calibration (since 2004-06-01)) 
5. CKD-EPI formula89: 
i. Woman, creatinine ≤ 62: 144 x [crea/(0.7x88.4)] -0.329 x (0.993)age 
ii. Woman, creatinine > 62: 144 x [crea/(0.7x88.4)] -1.209 x (0.993)age 
iii. Man, creatinine ≤ 80: 141 x [crea/(0.9x88.4)] -0.411 x (0.993)age 
iv. Man, creatinine > 80: 141 x [crea/(0.9x88.4)] -1.209 x (0,993)age 
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The terminal consequence of renal failure 
This basis of this thesis is the clinical problem of renal failure after heart 
surgery and cardiopulmonary bypass. As described above, renal failure is a 
potentially lethal complication. In brief, the following is the terminal 
pathophysiological consequences of renal failure95: 
Denied the eliminating services of the kidneys, the patient’s body will start to 
accumulate salt and water, causing swelling oedemas. The concentration of 
end products of protein metabolism, like creatinine, uric acid and urea also 
increases, causing the condition of uraemia. Since the kidneys are essential to 
the regulation of the acid-base balance through elimination of H+ and normal 
acidic products, acidosis will ensue as the pH drops below the normal 
physiological levels of 7.35-7.45.  
Within a week of total renal failure, the patient will slip into uremic coma as 
the cerebral neurons stops functioning, probably due to the build-up of 
hydrogen ions 
Death will occur when the pH of the blood reaches 6.8, if not before. 
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AIMS OF THE STUDY 
This thesis is based on four studies, all of which investigates renal function in 
relation to heart surgery.  These studies were designed and performed with 
the intention and hope that they might help to answer some of the questions 
that arise for clinicians when involved in the day-to-day clinical decision-
making regarding these patients.  
In particular, the following aims were identified: 
 
1. To investigate whether estimated GFR is an acceptable 
substitute for the more cumbersome, and expensive, 
methods of measuring GFR with either 51CrEDTA or 
Iohexole-clearance methods in patients eligible for heart 
transplantation (Paper I). 
 
2. To investigate how renal function both pre- and post-
transplantation affects mortality and morbidity after heart 
transplantation (Paper II). 
 
3. To investigate if, and possibly how, ANP affects renal 
function during CPB when given as a continuous 
prophylactic treatment starting before CPB is commenced 
(Paper III). 
 
4. To investigate whether priming the heart-lung machine with 
a solution with a higher-than-normal oncotic pressure could 
have any effect on kidney injury sustained during heart 
surgery and CPB (Paper IV). 
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PATIENTS AND METHODS 
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Patients 
Paper I and Paper II 
At the Sahlgrenska University Hospital, heart transplantations have been 
performed since 1980-ies, generating 478 HTx procedures between 1988 and 
2010. As part of the pre-HTx evaluation, the patients’ renal function have 
been assessed by measuring their GFR with the 51Cr-EDTA or iohexol 
methods. These patients have received annual follow-ups at our centre, which 
also have included the measurement of GFR through the same methods. We 
wanted to study the survival and the renal outcomes in the adult population 
(≥18 years) undergoing their first HTx, a total of 416 patients. Between 1988 
and 2010, 2190 GFR measurements were performed on these patients, of 
which 383 were preoperative and 1807 gathered during follow-up. These 
kidney function measurements registered in the HTx registers at the 
Sahlgrenska University Hospital, are the basis of the retrospective cohort 
studies performed in Paper I and II.  
In Paper II, the occurrence of renal replacement therapy was checked with the 
Swedish Dialysis Registry. 
Ethical approval to review the clinical data was obtained from the 
institutional review board at the University of Gothenburg (ethical approval 
no Dnr 728-12). 
Paper IV 
We wanted to assess, in humans, the renal effects (if any) of a colloid-based 
priming solution versus a standard crystalloid-based priming solution. 
PrimECC® is a new dextran 40 based priming solution (XVIVO AB 
Gothenburg, Sweden).  An investigator initiated double-blinded randomized 
study in adult patients undergoing heart surgery was designed. The study 
protocol was approved by the Gothenburg Regional Ethics Committee (Dnr T 
847-16 Ad 1003-15). The study was registered at ClinicalTrials.gov 
(identifier: NCT02767154). Written informed consent was obtained from all 
patients. 
The inclusion criteria were: all patients aged 50-80 years accepted for 
elective cardiac surgery with an expected CPB time above 75 minutes. 
Exclusion criteria were: previous cardiac surgery, coagulation disorder, 
malignancy, kidney failure, liver failure, on-going septicaemia, on-going 
antithrombotic treatment (other than acetylsalicylic acid), systemic 
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inflammatory disorders (treated with corticosteroids), or not able to 
understand Swedish language. 
In total, 39 patients were randomized to the colloid group (PrimECC- 
solution, dextran 40 based) and 41 to the crystalloid group (see Figure 8). 
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Animals 
In order to address the questions outlined in the third aim, we developed a 
pig-model for studying renal function during CPB (Paper III). The choice of 
using pigs in our experimental model depended on several factors. Pigs have 
hearts and kidneys whose anatomy and physiology are more similar to 
humans’ than many other animals. Also, we needed animals large enough for 
the cannulas and tubing fitted in our heart-lung machine system. Last, but not 
least, the animals had to be of practical size for the author to operate on. The 
pigs used in our study had a mean weight of 56 kg (range 47-64 kg) 
facilitating the feasibility of the surgical procedure, particularly the dissection 
of the renal hilum, and it´s structures (see Methods section). 
Pigs are prone to several 
infections that among other 
things can cause pleuritis, 
generating severe pleural ad-
herences. To avoid these 
problems, pigs can be bred in 
special farms controlled and 
guaranteed to be free of these 
pathogens, generating Specific 
Pathogen Free (SPF) animals. 
The animals used in our study 
were female Yorkshire pigs 
(Vallrum farm, Ransta, Sweden, 
specialized in producing SPF 
pigs) (Figure 4). 
In Sweden, performing animal 
experiments requires the primary 
investigator to pass an exam in 
Laboratory animal science and 
technique. Animal research is 
regulated in The Animal 
Protection act and the Animal 
Protection Ordinance. Ethical 
approval for this study was obtained from the Animal Research Ethical 
Committee of the University of Gothenburg (ethical approval no 107-2016). 
All animals received care in compliance with the Swedish Board of 
Agriculture regulations concerning research animals (SJVFS 2015:38). Pigs 
Figure 4: The author visiting the animal 
housing at the animal research facility. The 
housing conditions for research animals in 
Sweden are regulated in strict detail. 
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are social animals, and always require at least one other animal for company 
to avoid experiencing agonizing stress. In our study design, this meant that no 
pig could be left alone overnight for the last experiment, and that the last two 
pigs had to be anaesthetized simultaneously. Since we did not have two heart-
lung machines at our disposal to perform two parallel CPBs, the “companion 
pig” was used for sham-operation with continuous infusion of ANP. 
In total, 28 animals were operated on, of which twenty were randomized in 
the study (the other eight established the model, or were sham-operated). 
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Atrial natriuretic peptide (ANP) 
The atrial natriuretic peptide (ANP) used in this thesis is a recombinant 
human ANP drug used under license for treating AKI at the Intensive Care 
Unit at the department of Cardiothoracic surgery at the Sahlgrenska 
University Hospital, but otherwise not well known or used in Sweden. The 
drug has been approved for treating heart failure in Japan83, where it is also 
produced (Daiichi Sankyo, Japan). In the treatment of AKI, ANP has been 
shown to increase renal blood flow (RBF) and GFR and to decrease the need 
for dialysis in post-cardiac surgery patients. The effects of ANP on RBF, 
GFR and RVO2, when used for prevention in cardiac surgery with CPB are, 
to our knowledge, not well studied nor understood. In order to investigate the 
effects of ANP on kidney function during CPB we developed a pig model for 
invasive cardiothoracic and renal studies (Paper 3). 
Figure 5: The molecular structure of atrial natriuretic peptide (ANP) 
(Shutterstock, Standard license) 
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Dextran 40 
Dextrans are glucans, i.e. polysaccharide molecules made of long chains of 
glucose molecules, and come in a wide variety of lengths, from 3 to 2000 
kDa. First discovered by Lois Pasteur, the dextrans were introduced into 
medicine by Swedish scientists in the 1950’s, as colloids with properties 
making them suitable as possible plasma substitutes for treatment of 
hypovolemia, a much sought for product at the time96,97. Dextrans have a 
prolonged anti-thrombotic effect and have been used for anticoagulation 
therapy98,99. However, this anticoagulant effect may in some situations be 
unwanted, particular in the perioperative setting, and the colloid osmotic 
properties and anticoagulant effect has to be weighed against each other. 
The renal excretion of dextrans with a molecular weight over 50 kDa is very 
low100. Dextran 40 (also known as Rheomacrodex) however, is a 40-kDa 
glucan of which 70% is excreted in urine within 24 hours. This gives dextran 
40 distinct colloid properties, while at the same time being eliminated 
relatively rapidly compared to heavier dextrans (like dextran 70, also known 
as Macrodex) that can remain in the circulation for weeks. 
The effects of dextrans have been investigated in organ preservation studies 
with encouraging results101-103, leading to a recommendation that Dextran 40 
should be included in such solutions104. The oncotic properties in conjunction 
with the possible preservation effects and relatively short half-life, makes 
dextran 40 an interesting component in a CPB priming solution. We therefore 
wanted to compare a dextran 40-based priming solution to our standard 
crystalloid solution in a randomized, blinded study on adult patients 
undergoing heart surgery (Paper IV). 
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Methods 
This thesis is based on several studies of different design. Paper I and II are 
both retrospective longitudinal cohort studies, whereas Paper III describes a 
blinded, randomized study in animals, and Paper IV describes a double-
blinded, randomized controlled trial in humans. The principals of these 
studies, with their strengths and weaknesses are outlined below. 
Randomized controlled trials 
A controlled trial compares the outcomes of two groups when one group 
receives a specified intervention, and the other group do not. When 
designating patients to one of the two groups, there is always a risk that the 
investigators, or the patients themselves, consciously or inadvertently, affects 
the choice, or even other treatments given later on in the trial. The selection 
problem of this systematic error, or selection bias, can be minimized by 
randomly assigning the study subjects to either group. When possible, in 
order to further strengthen the internal validity of the study, either the 
subjects or the investigators, or both, can be blinded to the results of the 
randomization. This blinding reduces the placebo effect and observer bias.  
However, such a blinding often presents practical problems and is not always 
possible (e.g. when comparing a surgical treatment to a medical treatment). 
The first randomized controlled trial (RCT) in medicine was published in 
1948, regarding the treatment of tuberculosis with streptomycin105. Since 
then, RCT has become the gold standard method for investigating the effect 
of medical therapies. To improve and standardize the reporting of RCTs, the 
CONSORT 2010 Statement (Consolidated Standards of Reporting Trials) has 
been widely accepted. This includes the CONSORT-diagram that visualises 
the flow of the study subjects through the trial, and the number of subjects at 
each stage. Also, RCTs should be registered in the ClinicalTrials.com run by 
United States National Library of Medicine to increase transparency. In this 
thesis, CONSORT-diagrams were included in Paper II and IV.  
Disadvantages 
Even though the RCT is regarded gold standard in clinical research trials, it 
has certain disadvantages.  It can be very expensive studies to conduct, and 
take several years from planning of the study to the results being published. 
Studying interventions that are aimed at reducing infrequent events may 
demand very large numbers of study subjects, adding to the costs and time, 
and observational studies may therefore be a more practical alternative106, as 
in the case of renal failure and heart transplantation, mentioned above. 
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Due to the costliness of running RCTs, the investigators might be tempted to 
let the trials be sponsored by the pharmaceutical industry, which obviously 
may create concerns about conflict of interests. It has been shown that 
industry-sponsored RCTs are more likely to produce pro-industry findings107, 
and that industry-sponsored RCTs have lower odds for publication of 
completed trials than nonindustry-sponsored108. The possibility of publication 
bias cannot be ruled out as a cause of these differences. Conducting an 
investigator initiated study, i.e. with minimal funding from the industry, and 
where the results of the trial will be published regardless of the results, can 
reduce this problem. 
Another interesting problem is the ethics of such RCTs. Usually the reason 
for conducting a RCT is a well-grounded suspicion that a treatment could 
have some beneficial effect. But difficulties might arise as to decide the exact 
level of suspicion at which it becomes unethical to deny half of the study 
group the treatment. The final decision of such ethical problems lies with the 
ethics committees, weighing in all aspects of such a study.  
In this thesis, the design of an investigator-driven, double-blinded, 
randomized controlled trial was chosen when comparing the renal effects of a 
colloid-based priming solution to a standard crystalloid-based priming 
solution (see Paper IV). 
Registry studies 
Though randomized controlled trials are considered gold standard for 
comparing patient groups in a clinical setting (see above), certain 
circumstances can make these studies difficult to conduct from a practical 
point of view. In particular, studying patients receiving a relatively rare 
treatment (such as a heart transplantation) and the developing complications 
(such as death or ESRD) over a prolonged period of time (such as decades) 
would generate an immensely costly and logistically complicated study if it 
were to be designed as a prospectively, randomized follow-up study. A 
retrospective study however, can be conducted on existing data, or at least 
data that can be extracted afterwards. Thus, data that have been gathered 
continuously over the years and entered into an existing registry can make 
analyses possible, for e.g. descriptive purposes, which would otherwise not 
have been practically feasible. The limitations of such a retrospective study, 
however, are several. There will be multiple parameters that one does not 
know of, and that cannot be controlled. If part of the data retrieval is based on 
human memory, there will be the problem of selective memory, or recall bias. 
Patients may be lost in follow-up, or the data may simply not exist. Thus, 
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care must be taken when interpreting the results from such retrospective 
studies. Specifically, no causal links can be ascertained, at best only 
suggested.  
Despite the limitations of such retrospective studies, they have the advantage 
of being practical to perform, particularly when it comes to relatively rare 
diagnoses and complications during long-term-follow up106. Thus, in this 
thesis, two retrospective longitudinal cohort studies were conducted: One 
used existing data regarding renal function in an HTx cohort to compare the 
estimated GFR to the measured GFR over 10 years (see Paper I), a method 
comparison study (see statistics section). The other study compared the 
impact of different levels of pre-HTx GFR on survival and ESRD up to 20 
years after HTx (see Paper II). In this latter study risk factors for death and 
ESRD were also analysed. The statistical methods involved in such analyses 
include Kaplan-Meier survival analysis, the logrank test and Cox 
proportional hazard regression (see Statistics section). 
Animal studies 
For the study described in Paper III, we developed a large-animal model to 
study the effects of ANP on the kidneys during CPB in pigs. The invasive 
character of the planned renal investigations, necessitated the use of animals, 
not humans, to pursue the aim outlined above: to investigate if and possibly 
how, ANP affects renal function during CPB when given as a continuous 
prophylactic treatment starting even before CPB is commenced. In Sweden, 
the use of animals in experimental studies is regulated in The Animal 
Protection act (Djurskyddslagen) and the Animal Protection Ordinance 
(Djurskyddsförordningen). The surgical procedure is briefly described below. 
For further details and dosages, see Paper III. The study was designed as a 
blinded, randomized controlled study, in which 10 animals received a 
continuous infusion of ANP during CPB, and 10 animals received only saline 
(NaCl 0.9%). The results of the randomizations were not revealed to the 
investigators until the whole study was finished. Flow-chart of the 
experiment is depicted in Figure 6. 
Anaesthesia 
The animals were pre-medicated with an intramuscular injection of tiletamin, 
zolazepam and dexmedetomidin-hydrochloride. Anaesthesia was induced 
with thiopental and morphine infusions. An endotracheal intubation was 
performed and anaesthesia was maintained with a combination of thiopental, 
isoflurane and morphine. Fentanyl was given when needed. At the induction 
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methylprednisolone and amiodarone were given in order to provide stable 
cardiovascular function. 
Surgical preparation 
In the supine position, the right carotid artery and the right jugular vein were 
cannulated for measurements of arterial and central venous pressures, for 
blood sampling and for administration of fluids, respectively. The left jugular 
vein was catheterised for continuous infusion of 51Cr-EDTA (see below). 
Mean arterial pressure (MAP) and central venous pressure (CVP) were 
measured via pressure transducers at the level of the heart and calibrated to 
atmospheric pressure. A Foley catheter inserted in the urinary bladder 
sampled urine. The animals were laparotomised in order to expose the left 
kidney and the renal hilum. The renal artery and vein were identified and a 
Doppler flow probe was applied around the left renal artery and an 18 Gauge 
catheter was inserted into the renal vein for repeated blood sampling. A laser 
Doppler flow probe was sutured to the kidney surface for measurements of 
cortical perfusion. For medullary measurements, a needle laser Doppler probe 
was inserted 10-12 mm into the kidney. 
After completing the abdominal preparation, a sternotomy was performed. 
After heparinisation the arterial and the venous cannulas were placed in the 
ascending aorta and the right atrium and connected to a standard 
cardiopulmonary bypass circuit. 
Measurement of renal variables 
RBF and laser Doppler flowmetry (LDF) of the cortex and the medulla were 
continuously measured. The total RBF was assumed to be twice the blood 
flow to the left kidney. An intravenous priming dose of 51Cr-EDTA (0.6 
MBq/m2 BSA), (GE Healthcare Limited, The Grove Center, Amersham, 
UK), was given immediately after the introduction of the central venous 
catheter. This was followed by an infusion at a constant rate individualized to 
body weight. Serum concentrations of 51Cr-EDTA activity from arterial and 
renal vein blood were measured using a well counter (Wizard 300, 1480, 
Automatic Gamma Counter, Perkin Elma LAS, Turkuu, Finland). Renal 
vascular resistance was calculated from the formula: RVR=(MAP-
CVP)/RBF. Renal plasma flow (RPF) was calculated as: RBF (1-
haematocrit). GFR was calculated using the infusion clearance technique as 
the amount of infused 51Cr-EDTA divided by the arterial 51Cr-EDTA 
concentrations. Filtration fraction (FF) was calculated from the formula: 
GFR/RPF. RVO2 and renal oxygen extraction (RO2Ex) were derived from the 
formulas RVO2 = RBF x (CaO2 – CvO2) and RO2Ex = (CaO2 – CvO2/ CaO2) 
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(x100), respectively, where CaO2 and CvO2 are the arterial and renal vein 
oxygen contents. Renal oxygen delivery (RDO2) was calculated as RBF x 
CaO2. All renal data were normalised to the body surface area (BSA, m2) of 
the animals, which was calculated according to the female swine specific 
formula109 for BSA = 734 x (bodyweight in kg) 0.656. 
 
 
Figure 6: Flowchart depicting the timeline of the animal experiment. First sampling 
(PreTreatment) was immediately before ANP/NaCl-infusion was started, the next was 
1 hour later (immediately before CPB was commenced), then at regular intervals 
during 2 hours of CPB, and finally at regular intervals during 2 hours after CPB-
weaning.  Blood-gases were drawn every 30 minutes. 
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Statistical analysis 
Since this thesis is based on several different studies with different scientific 
designs, a range of different statistical methods has been applied. These will 
briefly be described below together with their applications, and their 
strengths and weaknesses. However, the actual mathematical equations will 
not be described. Mathematically interested readers are recommended further 
reading in Altman DG: “Practical statistics for medical research”, Campbell 
MJ: “Medical statistics” or Björk J: “Praktisk medicin för medicin och 
hälsa”. 
Correlation and Agreement 
When studying the association between to continuous variables, the method 
of correlation can be applied. The degree of correlation is stated in the 
correlation coefficient called r, and can take any value from -1 to +1, i.e. 
from a perfect negative correlation to a perfect positive correlation, and 
where 0 denotes no correlation at all. 
However, in medicine, a common clinical question is whether two different 
methods for measuring the same variable are equally good, and therefore 
potentially interchangeable. This question may arise out of practical reasons: 
One method might be more expensive or more cumbersome, and the clinician 
would like to know if it could be exchanged for a cheaper, quicker method. 
When comparing the two different methods for measuring the same variable, 
the most interesting question is of course to what degree the two methods 
come up with the same result, not only how well they correlate. It would be 
tempting to use correlation, but that would not be sufficient: whereas the 
correlation coefficient measures the degree of association between two 
groups, it says nothing about how closely they agree. Thus, in method 
comparison studies, agreement analysis is needed. 
The Bland-Altman agreement analysis110 calculates the mean difference 
between the two methods (called the bias, but not to be confused with the 
term “bias” in clinical experiments), as well as the standard deviation of these 
differences. The area around this bias up to ±2 standard deviations is called 
the limits of agreement. However, the practical importance of these limits of 
agreement might be difficult to interpret in a clinical setting. To get some 
idea about the degree of error between the methods, the width of the limits of 
agreement can be divided by the mean of the two measurements. The 
resulting percentage error gives an indication of how large the spread of the 
differences are, in relation to the absolute values of the method tested111. If 
the percentage error is 100%, the width of the limits of agreement (which is 2 
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standard deviations, or equal to the 95% confidence interval), is as wide as 
the absolute value of the mean of the methods being tested. Most clinicians 
would consider a percentage error of 100% unacceptably inaccurate, but there 
is actually no statistically defined cut-off at which the percentage error 
becomes unacceptable. What level of error should be considered 
unacceptable is therefore a strictly clinical consideration, which must take 
into account the gravity of the clinical consequences of the error for the 
patients. 
In this thesis, the method of measuring GFR was compared to the method of 
estimating GFR, using both Pearson product-moment correlation and Bland-
Altman agreement analysis (see Paper I). 
Student’s t-test 
In the process of improving the quality of stout, William Gosset, a statistician 
employed at the Guinness’ brewery in Dublin, invented a statistical method 
for describing a special case of normal distribution, which was later to be 
known as the t-distribution112. Since he was restricted from publishing 
corporate secrets, his method was published in 1908 under the pseudonym 
“The Student”. The difference between the standardised normal distribution 
and the t-distribution is that the t-distribution needs a wider interval to cover 
a certain percentage (e.g. 95%) of all the values in a population. 
The Student’s t-test tests to what degree the means of two sample groups 
reflect the same population. It returns the probability, p, that the means 
reflects the same population, provided that the null hypothesis is true (the 
null hypothesis being “they are the same”). Usually, a probability lower than 
5% (0.05) is considered statistically significant, and is presented as p<0.05. 
However, this implies that when performing this calculation repeatedly, 1 
result out of 20 could, statistically, still be a mere coincidence. 
Strictly speaking, the Student’s t-test is only valid provided the variances of 
the two populations are also equal. When this assumption of equal variances 
is dropped a slightly different test, the Welch’s t-test, is often employed. 
Also, the t-test assumes a normal distribution in the first place, which 
requires population samples of some size. Test that assumes a normal 
distribution of the study population are called parametric. In this thesis, 
comparing means with Welch’s t-test was performed when comparing the 
group of 39 patients that received colloid-based priming in the heart-lung 
machine, to the 41 that had crystalloid-based priming (see Paper IV). 
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Mann-Whitney U-test 
When comparing small sample groups, or groups where one cannot assume 
normal distribution, medians should be compared, instead of means. Using 
medians reduces the effect of a possible skewed population, and without the 
assumption of normal distribution these tests are called non-parametric tests. 
The non-parametric equivalent of the t-test is the Mann-Whitney test (also 
called Wilcoxon rank sum test, but not to be confused with the Wilcoxon 
signed rank sum test).  This test is recommended when comparing two 
groups containing less than 20 individuals each. In this thesis, the Mann-
Whitney test was used when comparing the two small-sized groups of pigs 
that were treated with either ANP or saline only, containing only 10 animals 
in each group (See paper III). 
Kaplan-Meier survival analysis 
In longitudinal studies, the occurrence of a specific incident (or hazard, when 
it comes to survival studies) in a population over time, can be plotted as a 
Kaplan-Meier plot.  The plot depicts the proportion of the population in 
which this incident has not occurred yet. On the Y-axis, the plot starts out on 
1 (maximum) or 100%. Then, as the incident occurs in the population, only 
those not affected are plotted. This generates a sloping curve that stops at the 
end of the follow-up period, at which time it may or may not have reached 
zero on the Y-axis. At each time-point only those individuals left in the 
population are included in the calculation, which means that the Kaplan-
Meier curve can be constructed despite individuals leaving the study for some 
reason, e.g. lost during follow-up. Since individuals are being censored with 
time (either because they die, or because they leave the study for some other 
reason) the resultant number of individuals left at each time point (the 
number at risk) should always be noted on the Kaplan-Meier plot. 
The hazards of interest in the retrospective longitudinal studies in this thesis 
were death and end-stage renal disease (see Paper II). 
Log-rank test 
The log-rank test is a non-parametric method for testing the null hypothesis 
that the groups being compared are samples from the same population. It is 
particularly designed to compare survival results over time, and the principle 
of the test is to divide the survival time scale into intervals, the intervals 
being defined by the observed occurrence of the hazard studied, and at the 
same time ignoring survival times of censored individuals (see Kaplan-Meier 
above). For each time interval the observed result is compared to an expected 
result, i.e. what we would expect if the null hypothesis were true (that they 
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are samples from the same population). The log-rank test can detect the 
existence of a difference between groups; however, it does not contain 
information about how different the groups are.  In this thesis, the log-rank 
test was used when analysing survival in patients undergoing heart 
transplantation (see Paper II). 
The log-rank test does not account for competing risks, e.g. death and renal 
failure. In the presence of such competing risks, Pepe-Mori’s test should be 
used113. This test compares the cumulative incidence functions for the event 
of interests, while taking into account competing risks. In this thesis, Pepe-
Mori’s test was applied when comparing the development of later end stage 
renal disease in patients that received CRRT due to AKI in the immediate 
post-operative phase (see Paper II).  
Cox proportional hazard regression model 
As opposed to correlation analysis, regression analysis not only states the 
strength of the relation between to parameters, but also gives a description of 
the relation. It enables us to make predictions about a value, when we only 
have the other. The principle is the generation of equations that describe the 
relations. Several regression techniques exist and can be applied depending 
on the values that are to be studied. The Cox proportional hazard regression 
model is a model particularly suited for survival data, and to assess hazard 
ratios. (If odds ratios are studied, logistic regression should be applied 
instead). 
The hazard ratio (HR) is a measure that describes the relative risk of death 
between two groups. It is the ratio between the hazard rates in the two 
groups, calculated for each time point. This gives an estimate of the relative 
event rates in the groups.  If the relative event rate in the first group is equal 
to that of the other group, the hazard ratio will be 1. If the rate is lower in the 
first group the hazard ratio will be <1, and vice versa. 
In survival studies, the hazard ratio is calculated for the entire time period 
studied. It is however possible that the hazard actually varies over time. The 
visual impression from the survival plot (Kaplan-Meier) is therefore an 
important complement. The term “Hazard ratio” implies that the calculations 
are not based on actual survival times (for which the term relative risk (RR) 
may be used), but rather on the proportions alive at the particular time-points. 
For continuous variables (like age), the Cox regression gives a hazard ratio 
that describes how the hazard is increased (or decreased) each added year of 
age. Univariate regression analysis handles only one variable at the time, but 
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when performing survival studies, several variables are usually of interests. 
Therefore multivariable regression analysis are usually applied, to take into 
account several variables and assessing their individual hazard ratios. 
Cox regression analysis is complex, and the results should be interpreted with 
care. It is generally recommended that a professional statistician be consulted 
when performing this analysis. 
In this thesis, Cox proportional hazard regression model was applied when 
analysing pre-transplant factors affecting post-transplant survival (see Paper 
II). 
ANOVA 
When studying variances between groups, it is also important to decide how 
much of this variance comes from variance within the groups, and how much 
arises from actual variances between the groups. The analysis of variance 
(ANOVA) deals with this problem. The larger the proportion of the total 
variance that depends on the variance between the groups, rather than within 
the groups, the stronger one can assume that the groups are different. 
ANOVA is used for structured data sets, which typically arise from designed 
experiments. In this thesis, ANOVA was used when studying differences 
between groups receiving ANP or saline in the animal study (see Paper III), 
and between groups receiving colloid-based or crystalloid-based prime in the 
randomized control study (Paper IV). 
  
Renal function in cardiac surgery – clinical and experimental studies 
54 
 
Oscar Kolsrud 
55 
RESULTS 
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Agreement of eGFR and mGFR in HTx (Paper I) 
The aim of Paper I was to compare measured GFR to the cheaper and simpler 
estimated GFR. The results of such a comparison could aid in the decision as 
to whether estimated GFR is an acceptable substitute for the more 
cumbersome and expensive method of measuring GFR with either 51CrEDTA 
or Iohexole-clearance methods in patients eligible for heart transplantation. 
Three of the most common formulas for estimating GFR were to calculate the 
estimated value, namely: Cockcroft-Gault, MDRD and CKD-EPI. Then both 
Pearson product-moment correlation and Bland-Altman Agreement analyses 
were performed to compare the results from the estimation formulas to the 
measured values (see Figure 7). 
 
 
The measured and the estimated GFR values were compared at defined time 
points: Both prior to transplantation (Pre HTx) and then at 1, 5 and 10 years 
after the procedure. Also, the bias, the percentage error and P30 were 
calculated. The results of these analyses are summarized in the tables 1 
through 5 below. 
 
 
Figure 7: Typical scatter-plots from Pearson product-moment correlation analyses 
(left) and Bland-Altman agreement analyses (right). This particular example 
illustrate correlation and agreement for GFR estimated with the MDRD formula, 
compared to measured GFR, at the 1st year of follow-up 
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Table 1: Correlation coefficients between estimated and measured GFR 
 Pre HTx 1 year 5 years 10 years 
Cockcroft-Gault 0.547 0.7 0.674 0.748 
MDRD 0.53 0.798 0.705 0.771 
CKD-EPI 0.53 0.8 0.7 0.815 
 
Table 2: Bias between estimated GFR 
 Pre HTx 1 year 5 years 10 years 
Cockcroft-Gault 9.9 10.5 12.8 14.4 
MDRD 1.7 2.3 2.1 3.1 
CKD-EPI 4.9 5.1 3.4 4.1 
 
Table 3: Limits of agreement between estimated and measured GFR 
 Pre HTx 1 year 5 years 10 years 
Cockcroft-Gault -30.4, 50.1 -25.4, 46.4  -23.4, 49.0 -15.4, 44.3 
MDRD -32.4, 35.8 -22.6, 27.2 -25.9, 30.2 -22.5, 28.8 
CKD-EPI -31.4, 41.2 -21.1, 31.3 -23.7, 30.5 -19.7, 28.0 
 
Table 4: Percentage error (%) between estimated and measured GFR 
 Pre HTx 1 year 5 years 10 years 
Cockcroft-Gault 126.0 134.5 157.3 144.6 
MDRD 107.6 93.3 121.7 124.2 
CKD-EPI 114.4 98.1 117.6 115.5 
 
Table 5: Percentage of estimated GFR results within 30% of measured GFR (P30) 
 Pre HTx 1 years 5 years 10 years 
Cockcroft-Gault 59.1 26.9 25.5 22.4 
MDRD 77.3 70.3 77.0 68.2 
CKD-EPI 67.4 64.3 73.3 65.9 
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GFR and outcome after HTx (Paper II) 
The aim of Paper II was to investigate to what degree measured glomerular 
filtration rate (mGFR) is a risk factor for death and/or end stage renal disease 
(ESRD) after heart transplantation (HTx). Also, we wanted to identify other 
possible risk factors, and investigate the impact of AKI early after the 
transplantation. All adult patients (n=416) who underwent HTx between 1988 
and 2010 were included; see CONSORT-diagram below. 
 
Eight patients concomitantly received a kidney transplant (KTx) at the same 
occasion as the HTx. Fifteen more patients had a late KTx due to severe 
chronic renal failure. The survival at 1, 5 and 10 years was 83%, 74% and 
59% respectively.  
In the multivariable Cox analysis, only age (as a continous variable) and the 
need for a ventricular assist device (VAD) were preoperative predictors of 
death (Table 6). 
Figure 8: CONSORT-diagram illustrating inclusion and exclusion of patients within the 
study population. 
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Preoperative mGFR however, was not a predictor for long-term survival, 
neither grouped (Figure 9, Table 6) or as a continuous variable (Table 6). 
 
 Table 6: Preoperative predictors of death (excerpt) 
 CI: confidence interval; VAD: ventricular assist device; mGFR: measured glomerular 
filtration rate. The Hazard ratio for age is per year. 
 
   Univariable Cox-regression Multivariable Cox-regression 
  n Hazard ratio 95% CI p 
Hazard 
ratio 95% CI p 
Age Cont. 416 1.02 1.01-1.03 <0.001 1.03 1.02-1.04 <0.001 
VAD No 323 1.00   1.00   
 Yes 57 1.48 0.98-2.23 0.060 2.23 1.43-3.46 <0.001 
mGFR <30 10 1.24 0.51-3.04 0.637    
(groups) 30-59 154 1.15 0.86-1.52 0.345    
 >60 219 1.00      
mGFR Cont. 393 1.00 0.99-1.00 0.283    
Figure 9: Survival after HTx. Patients stratified for preoperative mGFR: <30, 
30-59 and 60-. The differences were not significant (log rank p=0.6). 
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Preoperative predictors of later end-stage renal disease (ESRD) were diabetes 
mellitus and mechanical ventilation prior to HTx. However, preoperative 
mGFR did not predict ESRD (Table 7).  
Long-term survival was significantly worse for those experiencing a decrease 
in mGFR >25% during the first year after transplantation (Figure 10).  
 Table 7: Preoperative predictors of late ESRD (excerpt) 
ESRD: end-stage renal disease. CI: confidence interval. MV: Mechanical ventilation. 
 
   Univariable Cox-regression Multivariable Cox-regression 
  n Hazard ratio 95% CI p 
Hazard 
ratio 95% CI p 
Age  Cont. 406 1.01 0.99-1.04 0.27    
Diabetes No 239 1.00   1.00   
 Yes 40 2.56 1.31-4.98 0.006 2.39 1.15-4.99 0.02 
MV prior to No 337 1.00      
HTx Yes 23 3.08 1.21-7.82 0.018 3.49 1.36-8.99 0.009 
mGFR <30 6 4.13 0.97-17.5 0.06    
(groups) 30-59 151 1.20 0.67-2.16 0.55    
 60- 218 1.00      
mGFR Cont. 375 0.99 0.97-1.00 0.15    
Figure 10: Long-term survival conditioned on 1 year and stratified for different 
levels of GFR decline during first postoperative year (log rank p=0.073). In this 
analysis only patients were included that were alive after 1 year, and thereafter 
stratified according to GFR decline. The shaded area around the curves illustrates 
the 95% confidence interval. 
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The need for acute postoperative continuous renal replacement therapy 
(CRRT/dialysis) was associated with impaired survival (Figure 11) but did 
not predict ESRD among survivors (Figure 12).  
 
Figure 12: Survival of patients requiring early postoperative continuous renal 
replacement therapy (CRRT) in the ICU after HTx. Mortality was significantly higher 
in this group than in those without early renal failure, particularly during the first 
weeks/months (log rank p=0.0009, Hazard ratio 1.71, 95%CI 1.24-2.36). 
Figure 11: Pepe and Mori test comparing the cumulative incidence of events in the group 
that received early postoperative continuous replacement treatment in the ICU (CRRT), and 
those who did not. Those requiring early CRRT had a significantly increased risk for 
mortality (p=0.006) but the difference in later development of end-stage renal disease 
ESRD was not significant (p=0.09). Thus, those patients who survive early dialysis-
dependent acute renal failure do not have an increased risk for later development of ESRD. 
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ANP and kidney function during CPB (Paper III) 
In Paper III, we aimed to study the renal effects of extracorporeal circulation 
in the form of standard cardiopulmonary bypass (CPB), as routinely 
performed during heart surgery. In particular, we wanted to investigate 
whether atrial natriuretic peptide (ANP) could influence renal physiology if 
given during CPB. We designed an animal experiment that allowed for 
substantial invasive measurements of renal physiological variables, as 
described in Methods section. 
During the initial phase of establishing the procedure as a functioning model 
for CPB, three animals died before the intended protocol was completed. 
During the entire experiment, a total of five pigs were sham-operated, of 
which two also received ANP-infusion. When the experimental model was 
established, 20 pigs (mean weight 56 kg, range 47-64) were included and 
randomized to continuous infusion of either ANP or saline solution before, 
during and after CPB. 
We found no differences in mean arterial pressures (MAP) or renal perfusion 
pressures (RPP) between the groups during the procedure (Table 4-8). 
There were significant increases in GFR, diuresis and sodium excretion in the 
ANP group compared to the control group (p<0.001). Interestingly, there was 
no difference between groups during the first hour after start of the ANP-
infusion. Only after initiation of CPB did GFR increase significantly more in 
the ANP group at 60 (p=0.003) and 120 minutes (p=0.002), and even at 60 
minutes after weaning from CPB (p=0.023) (Figure 13, left). Diuresis and 
sodium excretion followed this same pattern, with a CPB-related increase, 
though even more pronounced (p<0.001 for both) (Figure 13 and 14).  
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Figure 13: GFR and diuresis during the experiment. Period on CPB is marked in 
light blue shading. Note the absence of difference between the groups until CPB 
is commenced.  
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RBF and RVR differed after weaning from CPB, but not during CPB. 
For calculation of RVR, FF, RVO2, RDO2 and RO2Extr see Methods section. 
As opposed to GFR and diuresis, filtration fraction (FF) rose in the ANP 
group already from the initiation of ANP-infusion, and stayed higher than the 
control group during the entire procedure (p<0.0001) (Table 8).  
 
 
Renal oxygen consumption (RVO2) (Figure 14) and renal oxygen delivery 
(RDO2) did not differ between groups, while renal oxygen extraction 
(RO2Extr) did  (p<0.001). RO2Extr was significantly higher in the ANP 
group 60 minutes after end of CPB (p=0.002).  
In the present study on the renal effects of ANP during CPB, ANP did not 
affect RVO2, despite the increase in GFR. 
Laser Doppler Flowmetry (LDF): 
Cortical perfusion measured with the LDF technique did not differ 
significantly between groups, and neither did medullary perfusion. However, 
when only NaCl was infused, the medullar perfusion did fall significantly 
relatively to the cortical perfusion during CPB (ANOVA p=0.036). In the 
ANP-group, no such reduction in medullar flow was observed 
(cortical/medullar flow p=0.88) (Table 9 and Figure 15).  
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Figure 14: Renal oxygen consumption (RVO2) and sodium excretion. There was no 
significant difference between groups with respect to RVO2. Sodium excretion 
followed the pattern that diuresis and GFR did. 
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 NaCl ANP p-value 
    
MAP (mmHg) ANOVA interaction: 0.21 
   
RPP (mmHg) ANOVA interaction: 0.13 
   
GFR (ml/min/BSA) ANOVA interaction: <0.0001 
   
Diuresis (ml/min/BSA) ANOVA interaction: <0.0001 
   
Na-excr (mmol/ml/min) ANOVA interaction: <0.0001 
   
RBF (ml/min/BSA) ANOVA interaction: <0.01 
   
Pre-treatment 554 (370-965) 534 (294-912) 0.74 
ANP/Placebo 1h 647 (386-945) 451 (372-571) 0.22 
CPB 1h 730 (497-1066) 720 (497-834) 0.74 
CPB 2h 856 (519-1260) 692 (552-902) 0.28 
Post CPB 1h 694 (428-909) 389 (313-451) <0.01 
Post CPB 2h 519 (346-605) 314 (217-455) <0.05 
    
RVR (mmHg/ml/min) ANOVA interaction: <0.01 
    
Pre-treatment 0.145 (0.082-0.178) 0.132 (0.079-0.259) 0.76 
ANP/Placebo 1h 0.113 (0.076-0.166) 0.141 (0.109-0.189) 0.17 
CPB 1h 0.099 (0.065-0.149) 0.090 (0.078-0.135) 0.70 
CPB 2h 0.089 (0.089-0.148) 0.099 (0.079-0.139) 0.56 
Post CPB 1h 0.084 (0.071-0.145) 0.134 (0.111-0.173) <0.05 
Post CPB 2h 0.110 (0.092-0.158) 0.131 (0.108-0.212) 0.128 
   
FF ANOVA between animals: <0.0001 
    
Pre-treatment 0.271 (0.239-0.321) 0.312 (0.260-0.343) 0.28 
ANP/Placebo 1h 0.279 (0.248-0.301) 0.380 (0.329-0.413) 0.01 
CPB 1h 0.254 (0.240-0.274) 0.309 (0.282-0.343) 0.0004 
CPB 2h 0.227 (0.222-0.243) 0.352 (0.317-0.406) 0.0019 
Post CPB 1h 0.313 (0.294-0.320) 0.432 (0.394-0.450) <0.0001 
Post CPB 2h 0.294 (0.208-0.341) 0.377 (0.282-0.435) 0.065 
    
Table 8: Renal and circulatory parameters. The table has been shortened for 
brevity. Where the ANOVA did not show significant difference between groups, 
the p-values for the repeated measures have been omitted.  GFR, diuresis, sodium 
excretion and RBF are illustrated in figures above. 
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Table 9: Laser Doppler Flow (LDF) measurements. 
 Cortex Medulla p-value 
   
LDF (NaCl) ANOVA interaction: 0.036 
    
Pre-treatment 100 100 NA 
ANP/Placebo 1h 116 (98-127.5) 94 (90-117) 0.25 
CPB 1h 106 (84-130) 82.5 (48.5-89.8) 0.027 
CPB 2h 119 (75.5-162) 69.5 (45-136.8) 0.28 
Post CPB 1h 106 (77.5-138) 93 (66-108) 0.39 
Post CPB 2h 103 (76.5-124) 98 (66-118) 0.68 
    
LDF (ANP) ANOVA interaction: 0.88 
    
Pre-treatment 100 100 NA 
ANP/Placebo 1h 90 (78-105.5) 107 (92-161.5)  
CPB 1h 91 (75-124.5) 107 (92-161.5)  
CPB 2h 103 (78.5-119) 121 (35-157.5)  
Post CPB 1h 80 (72-105.5) 92 (61-102)  
Post CPB 2h 75 (60.5-94.5) 84 (64.5-157.5)  
    
LDF measurements from renal cortex and medulla. The results of LDF measurements are 
unitless “Flow Units”, and therefore normalised to value “100” at initiation of experiment. All 
numbers are medians (IQR). Where ANOVA is significant, p-values for individual time points 
are shown. NA: Not applicable. 
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Figure 15: LDF measurements from renal cortex and medulla. When only saline 
solution is given, the flow in the medulla drops during CPB (left), and then recovers. 
This pattern disappears when ANP is infused (right). 
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There was no accompanying significant difference in the release of tubular-
injury marker u-NAG between groups (Figure 16). 
 
 
 
 
Figure 16: Tubular injury marker u-NAG/u-creatinine ratio during the 
experiment. There was no significant difference between groups. Period 
on CPB is marked in light blue shading. 
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Colloid- vs crystalloid-based prime (Paper IV) 
The aim of Paper IV was to compare the renal effects of two different 
priming solutions for the heart-lung machine: A colloid-based and a standard 
crystalloid-based priming solution, respectively. The colloid of choice was 
dextran 40. The PrimECC study was designed as an investigator initiated, 
double-blinded, randomized controlled trial in patients undergoing cardiac 
surgery with cardiopulmonary bypass (CPB). In all, 39 patients were 
randomized to the colloid-based prime and 41 to the crystalloid-based prime. 
!
Assessed for eligibility (n = 135) 
Excluded  (n=51) 
♦!!!Not meeting inclusion criteria (n=14) 
♦!!!Declined to participate (n=11) 
♦!!!Logistic reasons (n=21) 
♦   Participated in another study (n=4) 
♦   Other reasons (n=1) 
 
 
Analysed  (n= 39) !
Followed-up (n=39) 
Excluded after intervention (n=3) 
      One change of operation method (aortic resection in  
      cardiac arrest), one cardiac arrest at induction,  
      ongoing CPR to CPB, one patient underwent  
      intraoperative ultrafiltration (5L) 
 
Allocated to dextran prime (n=42) 
♦!Received allocated intervention (n=42)!!
Followed-up (n=41) 
Allocated to crystalloid prime (n= 42) 
♦ Received allocated intervention (n= 41) 
♦ Did not receive allocated intervention (n=1)  
One due to cancelled operation because of   
accident-ally discovered aortic dissection 
immediately after anesthesia induction. 
Analysed  (n= 41)!
Allocation)
Analysis)
Follow.Up)
Randomized (n=84) 
Enrollment)
Figure 17: CONSORT diagram showing the inclusion and exclusion of patients in 
the PrimECC study. 
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The baseline characteristics between the groups did not differ significantly; 
neither did the intraoperative data, except for the time on CPB, which was 
91±25 minutes for the dextran 40-group versus 107±39 minutes for the 
crystalloid group (p=0.042). Aortic clamp time and total operation time did 
not differ. Nor was there any difference in mean arterial pressure (MAP) 
during CPB or the type of procedures. 
As expected, colloid osmotic (oncotic) pressure was higher in the dextran 40- 
group during and immediately after CPB. Serum haemoglobin and 
haematocrit followed an inverse pattern (Table 10). Within 2 hours however, 
these effects had already disappeared. 
 
 Table 10: Results: non-renal parameters 
 
There was no difference in 30-day mortality, ICU stay, reoperation for 
bleeding or postoperative AKI (measured as a rise in serum creatinine 
according to KDIGO criteria). 
 Dextran 40 (n=39) Crystalloid (n=41) p-value 
    
Oncotic pressure (mmHg) ANOVA interaction: <0.0001 
Preoperative 19.9±2.8 20.7±3.1 0.24 
During CPB 18.8±2.9 16.4±2.9 <0.001 
Post CPB 10 min 19.2±2.7 16.8±2.9 <0.001 
Post CPB 2h 19.5±3.1 18.6±3.2 0.20 
Post CPB 24h 20.7±3.1 21.0±3.5 0.62 
    
Haemoglobin (g/L) ANOVA interaction: 0.008 
Preoperative 125±14 126±14 0.80 
Post CPB 2h 107±10 115±12 0.001 
Post CPB 24h 109±11 109±13 0.79 
   
Haematocrit ANOVA interaction: 0.03 
Preoperative 0.36±0.05 0.37±0.04 0.43 
Post CPB 2h 0.31±0.03 0.34±0.04 0.002 
Post CPB 24h 0.32±0.03 0.32±0.04 0.78 
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The crystalloid group required significantly more volume substitution during 
CPB, and the total fluid balance (which was net positive in both groups) after 
the first 12 hours was 24 % higher in the crystalloid group (Table 11). 
 
 Table 11: Fluid balance (ml) peroperatively until first 12 hours postoperatively 
 
During CPB, diuresis was significantly lower in the dextran 40-group than in 
the crystalloid group. Since CPB time differed between groups, the diuresis 
was also calculated per minute on bypass (ml/min/BSA) but was significantly 
lower nonetheless (Table 4-12).  
Renal tubular injury, assessed by analysing the u-NAG/u-creatinine ratio, 
was less pronounced in the group receiving dextran-40 based colloidal 
solution as a pump prime compared to the crystalloid group (Figure 18, Table 
12). 
 
 Dextran 40  
(n=39) 
Crystalloid 
(n=41) 
P-value 
Peroperative 555±595 841±574 0.031 
Postoperative first 12h iv 876±677 1060±745 0.251 
Postoperative first 12h iv + oral 1221±808 1360±797 0.440 
Total preop +postop iv 1431±741 1901±922 0.014 
Total preop +postop iv + oral  1775±866 2201±1011 0.047 
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Figure 18: Ratio of NAG to creatinine in the urine. At 1 hour after CPB, this 
tubular injury marker was higher in the group that received crystalloid priming 
solution. 
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Table 12: Renal parameters 
CPB: Cardiopulmonary bypass. S-creatinine: Serum creatinine. U-NAG/Ucreatinine: urinary 
NAG/creatinine ratio 
 
 
 
 Dextran 40 (n=39) Crystalloid (n=41) p-value 
    
Diuresis (ml/BSA) ANOVA interaction: 0.014 
    
Perop, no CPB 221±172 177±113 0.18 
During CPB (ml/BSA) 47±62 126±94 <0.0001 
During CPB (ml/min/BSA) 0.53±0.76 1.23±0.83 0.0002 
Post CPB 12h 800±261 730±220 0.31 
Post CPB 24h 416±160 456±144 0.83 
    
S-creatinine (µmol/L) ANOVA interaction: 0.35 
    
Peak s-creatinine 110.6±43.5 113.8±49.56 0.76 
    
eGFR (ml/min/1.73m2) ANOVA interaction: 0.60 
    
Lowest eGFR 60.6±20.3 59.9±21.2 0.87 
    
Urinary Sodium (mmol/L) ANOVA interaction: 0.022 
    
Preop 96.1±41.0 95.8±35.5 0.97 
During CPB 73.7±34.9 54.0±27.3 0.007 
Post CPB 1 hr 89.5±36.4 68.0±32.5 0.007 
Post CPB 24 hrs 44.3±25.7 45.5±23.3 0.83 
    
U-NAG/U-Creatinine ANOVA interaction: 0.038 
    
Preop 0.5±0.3 0.5±0.3 0.35 
During CPB 1.2±0.7 2.8±5.7 0.11 
Post CPB 1h 2.5±2.7 4.7±6.3 0.045 
Post CPB 24h 1.2±1.2 1.0±0.5 0.33 
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DISCUSSION 
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Paper I 
 
Main findings 
The main finding in the study presented in Paper I was that the estimated 
GFR values using three of the most common estimating equations for this 
purpose (the Cockcroft-Gault, the MDRD or the CKD-EPI formulas), agrees 
poorly with the measured values, in a HTx cohort. This poor agreement was 
found both before HTx and at follow-up 1, 5 and 10 years after 
transplantation. 
The Pearson’s product-moment correlation analysis showed strong positive 
correlations of the follow-up comparisons of eGFR and mGFR (r > 0.7), but 
poor agreement according to the Bland-Altman agreement analyses that 
consistently yielded percentage errors around or above 100%. The finding 
that P30, the percentage of the estimated GFR results that comes within 30% 
of the measured GFR values, with only two exceptions was below 75% 
confirmed a low level of precision114.  
As clinicians, we argue that the level of agreement between estimated and 
measured GFR in HTx-patients is unacceptably low, and that measured GFR 
should be used in this patient group. 
Study in perspective 
Our study included 383 adult patients receiving HTx, and the comparison of 
GFR-estimating formulas and measured GFR comprised both pre-HTx values 
and follow-up values, with an average follow up time of 8.9 years (SD±6.96 
years) years. We thus could conduct both pre-HTx comparisons, as well as 
comparisons at 1, 5 and 10 years after HTx.  
To our knowledge, this is the first study to specifically address both the pre-
HTx and long-term follow-up applicability of eGFR in a complete cohort of 
heart transplanted patients. 
The study was performed on a very specific group of patients: Those with a 
severely failing heart who underwent heart transplantation. These patients 
have several risk exposures that may influence their kidney function, which 
separates them from other patients: Their pre-transplant renal function may 
be affected by their severe heart failure, they are exposed to major surgery 
and the heart-lung machine, and finally their kidneys are exposed to long-
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term immunosuppressive treatment, drugs that have documented nephrotoxic 
effects. Thus, the results of this study should only be interpreted in the 
context of this particular patient group. 
On the other hand, a comprehensive review93 of the current status of the 
precision of the GFR estimation formulas in 2013 concluded that very little 
data existed concerning organ-transplanted patients. In particular, one could 
only identify one study concerning heart-transplanted patients; and this only 
included 27 patients115. That study indicated that the estimated GFR agreed 
poorly with measured GFR. Another study included 43 HTx patients116, but 
only used Pearson correlation, not Bland-Altman agreement analysis. None 
of those studies analysed pre-HTx GFR, and there were no longitudinal data. 
We believe that our study contributes with important knowledge about the 
(lack of) agreement between estimated and measured GFR in this particular 
group, and we consequently decided to continue with mGFR in our clinical 
routine. 
Study limitations 
Even though our study is the largest in this patient group so far, it has several 
limitations. The general limitations of a retrospective cohort study are 
outlined in the statistics section 3.5.2. In our study, there were missing data at 
all time-points; both before HTx and during follow up. Thus, missing data 
made it impossible to analyse 7.9% of patients before transplantation, 18% at 
1 year, 34% at 5 years and 42% at 10 years. This of course generates 
increasing uncertainty about the results as the time from HTx increases. 
However, since the results of the agreement analyses stay within the same 
intervals, we believe that a complete data set would not alter the results.   
Another limitation is the formulas not explored: The LM-rev equation was 
not included in the study since this was not regarded as one of the formulas 
applied worldwide. There also exist formulas that are based on cystatin C, but 
no cystatin C samples was drawn from any of our patients, and therefore no 
such analyses could be performed in our cohort. 
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Paper II 
 
Main findings 
The main finding in this study of heart transplantation patients was that the 
patients’ pre-transplantation kidney function did not predict mortality or later 
end stage renal disease, not even in the patients with a pre-transplant GFR 
less than 30 ml/min/1.73m2. These results were achieved in a transplant 
program offering simultaneous or later kidney transplantation. We argue that 
this result indicates that a severely impaired renal function should not 
automatically exclude a patient from HTx-consideration, if otherwise eligible 
for HTx. 
However, we also found that a drop of more than 25% during the first year 
after transplantation had a poorer prognosis than those with a first-year drop 
of < 5%. (HR 1.62; 95 % CI 1.04-2.53; p=0.03). Whether this finding is just 
describing a co-variance with some other factor affecting the survival in this 
group, or whether there exists some sort of causality, this observational study 
cannot answer. 
In consistency with other studies, patients that developed postoperative acute 
kidney injury requiring renal replacement therapy (dialysis) had a 
significantly shorter long-term survival (HR 1.71; 95% CI 1.24-2.36; 
p=0.0009). 
Study in perspective 
Over the years, pre-transplant renal function has been considered an 
important factor to weigh in when assessing a patient’s eligibility for HTx. 
This is a reasonable policy, since the incidence of chronic renal failure 
accumulates with increasing time after all solid-organ transplantation. The 
rationale behind a restrictive policy regarding the lowest acceptable level of 
pre-HTx kidney function is of course to maximise survival and minimise the 
risk of later end stage renal disease. However, controversy still remains about 
the exact level at which a reduced GFR should be considered a risk factor for 
transplantation. This is reflected in the development of the ISHLT guidelines 
regarding eligibility for HTx. At the 24th Bethesda conference in 1993, a 
creatinine clearance less than 50 ml/min was considered secondary exclusion 
criteria for HTx38. In 2006, the International Society of Heart and Lung 
Transplantation (ISHLT) recommended that a pre-transplant GFR of 40 
ml/min/1.73m2 or less should be considered as a relative contraindication to 
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HTx39. In the ISHLT 2016 guidelines this level was further reduced to less 
than 30 ml/min/1.73m2. Below this level, the renal function is considered a 
relative contraindication for HTx40.  
The problem with impaired renal function in patients eligible for HTx might 
be a pre-renal problem since the kidneys might be suffering under the low 
cardiac output from the failing heart, but may be otherwise unaffected, and 
will have the potential to regain their normal function once the failing heart is 
exchanged for a new, healthier one. Therefore, a better procedure for pre-
HTx evaluation of the actual GFR should be developed.  
Despite the limitations described below, we believe that this study adds 
important information regarding clinical decision-making in HTx-recipients: 
both during the pre-HTx evaluation and later, during follow-up. We argue 
that this study demonstrates that a poor pre-HTx renal function should not 
automatically exclude a patient from HTx. Also, during follow-up, the GFR 
should be especially closely monitored during the first 12 month, since a drop 
in GFR of more than 25% in this period is associated with a shorter long-term 
survival. 
However, we realise that these arguments only are valid if the HTx centre is 
capable of offering a wide range of treatments, including that of kidney 
transplantation if needed. This study cannot give any definitive answers 
about causality, or if any intervention actually can alter the prognosis. To 
answer such questions will need a prospective randomized controlled trial, 
and that might be difficult to perform, since it will be a very expensive and 
time-consuming study. 
Study limitations 
This single-centre retrospective longitudinal cohort study suffers from the 
same limitations mentioned for Paper I, chapter 5.1 above. Though 416 HTx 
recipients were included in the study, missing data reduced the numbers 
actually possibly to calculate risk factors on by as much as 7.9 % (see Figure 
4-2). There is also most certainly a selection bias, particularly in the group 
with the lowest pre-HTx GFRs. These patients have probably been accepted 
for HTx due to other factors strongly in favour of transplantation. 
Also, even if the log-rank analysis of the Kaplan-Meier survival curve was 
significant, the number of patients with a pre-HTx GFR < 30 ml/min/1.73m2 
was low, only 10 individuals, and after 5 years of follow-up so few that 
conclusions are difficult overall. This necessitates caution when interpreting 
the results. 
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Paper III 
 
Main findings 
The main finding in Paper III was that a continuous infusion of atrial 
natriuretic peptide could increase GFR during cardiopulmonary bypass. This 
was caused by pre-glomerular vasodilation and post-glomerular vasodilation, 
as reflected by the increase in renal filtration fraction. As the GFR is the 
major determinant of renal oxygen consumption, one would have expected 
that ANP should have increased renal oxygen consumption, which was not 
the case.   
Study in perspective 
The frustrating lack of existing modalities for effective prevention or 
treatment of postoperative AKI, calls for investigation of any substance that 
can potentially exhibit renoprotective properties71. Studies have indicated that 
ANP may be such a substance81,117,118, but the drug has mostly been 
administered after CPB, or when the AKI already is manifest. The existing 
evidence is contradictory. 
During and after CPB, the renal oxygen extraction increased with ANP, 
suggesting an impairment of the renal oxygen supply/demand relationship. 
Despite this, there was no increase in the tubular injury marker NAG. These 
findings indicate a potential renoprotective effect of ANP during CPB. 
This lack of difference in renal injury despite the ANP-induced impairment 
of renal oxygenation (=impaired renal oxygen supply/demand relationship) 
could be explained by an ANP-induced inhibition of tubular sodium 
reabsorption in the medullary collecting duct, which would decrease RVO2. 
This would protect the tubuli from the increased energy demand and oxygen 
consumption caused by the ANP-induced increase in sodium filtration and 
increased tubular sodium load. 
This animal study thus supports the notion that ANP not only improves renal 
function but also seem to protect the kidney from the potential negative 
consequences of the increase in GFR, by blunting the increase in renal 
oxygen demand, otherwise seen when an agent increases GFR. 
It is well known that the normal medullar perfusion is only a fraction of the 
cortical blood flow119,120. However, the CPB-related reduction of the blood 
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flow in the renal medulla was a new and unexpected finding. In the animals 
that only received saline infusion, the medullar perfusion seemed to decrease 
relative to the cortical perfusion, an effect that was not seen when ANP was 
infused. The ANP-induced maintenance of medullary flow perfusion during 
CPB could be another renoprotective effect of ANP, as the medulla is 
particularly sensitive to impaired perfusion. The mechanisms by which the 
CPB should induce such an effect are as yet unclear to us, as well as the 
pharmacological mechanisms behind the registered effect of ANP. An 
obvious difference between the normal circulation and the CPB-circulation is 
the non-pulsatile character of circulation induced by the CPB. However, it is 
unlikely that this pulsatility even under normal circumstances reaches the 
glomerular capillaries121,122. The findings in this study that CPB and ANP 
affect medullar perfusion will have to be repeated in larger animal studies, 
and in humans, before one can draw any certain conclusions from it. 
However, if these results stand up to repeated scrutiny, they may point to a 
hitherto unknown aspect of renal physiology. 
To investigate the possible renoprotective effects of ANP further, randomized 
controlled studies in humans are necessary, particularly in the setting of heart 
surgery and CPB. 
Study limitations 
An inherent uncertainty in all animal studies is of course whether or not the 
findings also apply to human physiology. However, the fact that the animals 
reacted with increased GFR and increased diuresis to this human peptide 
hormone, points to at least some similarities in renal physiological response. 
The question of applicability of our results in humans can only be fully 
answered by studies in humans.  
Another limitation of this study is that he numbers of animals included was 
limited, comprising only 10 animals in the treated group and 10 in the control 
group. Consequently, even if the statistics used have been adjusted to take 
this into account, the possibility that either a statistical error type I or type II 
may have occurred cannot be ruled out. 
One could also question the use of human ANP for the evaluation of its renal 
effects in pigs. However, human ANP has been extensively used in 
experimental animal research, including pigs, using similar infusion rates as 
in the present study. Also, as mentioned above, the animals in this study 
responded to the human drug in an at least partly expected fashion, with 
increased GFR, diuresis and natriuresis.  
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Paper IV 
 
Main findings 
The main finding in paper IV was that the patients that received dextran 40-
based priming solution had significantly lower release of the tubular injury 
marker U-NAG than those who received standard crystalloid priming 
solution (p=0.038). Also, their oncotic pressure was significantly higher 
during and immediately after CPB (p<0.0001). These findings suggest that a 
colloid-based priming solution might induce less kidney damage than a 
crystalloid-based one. 
However, and importantly, there were no differences between groups 
regarding clinical renal outcomes, such as AKI or CRRT, or even s-creatinine 
or eGFR. 
Study in perspective 
The use of colloids in the priming solution of heart-lung machines has been 
debated for decades, and the results have been contradictory. Studies on 
colloid infusion in general have raised concerns about the safety of 
colloids123-125. Currently, crystalloid-priming solution seems to be the most 
common choice, with colloid priming being used in less than 25% of cardiac 
surgery centres around the world11,12.  
However, considering the looming clinical problem of post-CPB acute 
kidney injury and renal failure, the fact that colloid solutions have at least 
theoretically favourable properties when it comes to preserving renal 
function, makes continued research in this area necessary. 
Dextran 40 is a molecule with colloid properties that at the same time are 
eliminated relatively quickly from the circulation. The potential advantage of 
such a molecule is that it could provide the assumed beneficial effects of a 
preserved microcirculatory colloid osmotic pressure during CPB, while at the 
same time avoiding prolonged negative effects on haemostasis thanks to the 
shorter half-life than larger dextrans. 
This is, to our knowledge, the first randomized controlled study comparing 
the renal effects of a dextran 40-based and crystalloid-based priming solution. 
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What then, could be the reason for the less pronounced level of the tubular 
injury marker in the colloid group in this study? NAG has been shown to be a 
sensitive detector of AKI in cardiac surgery52,53. It has recently been shown 
that both colloid and crystalloid plasma volume expansion induces 
haemodilution. However, neither the colloid nor the crystalloid increases 
oxygen delivery, despite the fact that they both increased RBF126. However, 
GFR and renal oxygen consumption increased in the crystalloid but not in the 
colloid group. This may be because of the higher oncotic pressure in the 
glomeruli, preserving more fluid in the intravascular space and thus reducing 
the fluid load on the tubuli. Since the major determinant of renal oxygen 
consumption is GFR, the crystalloid solution induces a renal oxygen 
supply/demand mismatch, since the oxygen delivery was not increased 
proportionally, which was not seen with the colloid. It is plausible that the 
more pronounced renal tubular injury seen with the crystalloid, in the present 
study, could be explained by a more pronounced impairment of renal 
oxygenation, when compared with the colloid. In our study, serum creatinine 
was not sampled until 24 hours after CPB, and hence eGFR could not be 
calculated during or immediately after CPB. Thus, a possible explanation for 
the lower NAG/u-creatinine-ratio seen in the colloid group in this study 
might be that the higher oncotic pressure had a renal protective effect in 
reducing the renal oxygen consumption, and thus reducing renal hypoxia and 
tubular damage.  
Also, in our study, the crystalloid required more fluid substitution during 
CPB, and the total accumulated fluid administration and fluid balance during 
surgery and the first 12 hours afterwards was significantly higher in the 
crystalloid group, indicating a higher level of tissue oedema also in the 
kidneys. Haemodilution with crystalloid solution has earlier been shown tin 
experimental studies to be associated with hypoxia-inducible factor 1α and 
renal tissue oedema127. 
Thus, both oxygen supply/demand mismatch and renal tissue oedema 
formation could be the reason for increased tubular injury in the crystalloid 
group in our study. 
The fact that we could not demonstrate any differences in clinical outcome 
could have at least four different explanations:  
• There might be no connection between the elevated NAG-
levels and any clinically significant renal damage, expressed 
as increased levels of serum creatinine. 
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• The tubular injury was not large enough to detect a renal 
dysfunction, assessed by an increase in serum creatinine. 
• There might be too few patients included in the study to 
identify a true difference in clinical outcome (type II error). 
• The patients included in the study might have had a too low 
risk for the development of AKI for this strategy (colloid-
based priming) to have any effect on renal outcome. 
Since patients with a GFR <30 were excluded from inclusion into this study, 
it follows that those with the most vulnerable kidney function were not 
studied. Also, the mean estimated GFR of the patients included was 77 
(77.11±7,9 in the dextran 40 group vs 77.07±18.04 in the crystalloid group, 
p=0.85), which is quite good. One might speculate that patients with a worse 
kidney function, already on the verge of kidney failure or dialysis might 
benefit the most from a strategy to protect kidney function during CPB, and 
would generate a difference even in clinical outcomes. To answer this 
question one would need to repeat the study in a high-risk population with a 
lower mean GFR, including even those with the worst kidney function. 
Study limitations 
The main limitation of this study was that the number of patients included 
was too low to detect any differences in renal outcome. Also, patients with a 
pre-operative GFR <30 were excluded altogether, and the mean GFR of the 
patients included was 75-80, indicating that the renal function in this group 
might be to good to be significantly affected by any strategy to increase their 
colloid osmotic pressure. Also, a future study should have some strategy for 
measurements of GFR during and immediately after CPB. 
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CONCLUSIONS 
Based on the results from papers included in this thesis, we conclude the 
following: 
• In heart transplantation recipients, a method comparison 
analysis of three of the most common equations for 
estimating GFR revealed that the estimated values are in 
unacceptably poor agreement with the actual measured 
values. We therefore recommend that measured GFR, not 
estimated, should be used when assessing renal function in 
heart transplantation recipients.  
 
• Offered optimal therapy, including kidney transplantation, 
kidney function before heart transplantation does not predict 
mortality or later end stage renal disease, not even in the 
patients with a pre-transplant GFR less than 30 
ml/min/1.73m2. We argue that a severely impaired renal 
function should not automatically exclude a patient from 
HTx-consideration, if otherwise eligible for HTx. 
 
• Atrial natriuretic peptide (ANP) increased glomerular 
filtration rate in an experimental model of cardiopulmonary 
bypass (CPB) caused by a pre-glomerular vasodilation and a 
post-glomerular vasoconstriction. Results also suggested 
that ANP might have a renoprotective effect. To investigate 
these results further, we recommend further studies in both 
animals and humans.  
 
• A colloid-based priming fluid for heart-lung machines 
containing dextran 40 reduced renal tubular damage, 
assessed by urinary NAG/creatinine ratio. We recommend 
that further studies investigating the effect of dextran 40 
based priming solution on patients with preoperatively 
impaired kidney function undergoing heart surgery and 
CPB, should be performed. 
. 
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FUTURE PERSPECTIVES 
The results of the studies described in this thesis, and the conclusions we 
draw from them, not only points to future studies but may also have 
immediate clinical implications for patients undergoing heart surgery:  
Based on our studies, we recommend that renal function in heart 
transplantation recipients should be assessed with measured GFR, not 
estimated. It is worth noting that at the start of the study on estimated GFR 
(Paper I) our interest lay in exchanging our tradition of measuring GFR with 
the cheaper and quicker method of estimation. However, our study has 
convinced us to continue with measurements instead of estimations of GFR. 
We believe this strategy will give the most exact assessment of the patients’ 
kidney function, and thus give us, their physicians, the best basis to decide on 
the most optimal treatments at the most optimal time.   
Also, the results from Paper II have an immediate clinical application. When 
evaluating the eligibility for heart transplantation in patients with a severely 
reduced kidney function, our results indicate that no one should be excluded 
solely on the basis of their GFR. In the future, pre-transplant GFR should be 
considered important for designing a treatment strategy for the individual 
patient, such as concomitant kidney transplantation, but not for excluding 
them from heart transplantation. 
Paper III and Paper IV points towards further studies: We need to establish 
with certainty whether ANP really has renoprotective properties, and if so, 
elucidate the mechanisms behind this property. Also, we need to design 
further studies to investigate how cardiopulmonary bypass affects medullar 
perfusion, and by what mechanisms.  
Paper IV indicates that colloid-based priming with dextran 40 induces less 
tubular damage than crystalloid. Yet we need more studies to establish 
whether this effect also has clinical impact. Therefore, new randomized 
controlled trials in humans are warranted, particularly in patients with a 
preoperatively impaired kidney function, even with a GFR as low as <30 
ml/min/1.73m2. 
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